Immediate release abuse deterrent liquid fill dosage form

Information

  • Patent Grant
  • 9707184
  • Patent Number
    9,707,184
  • Date Filed
    Tuesday, July 7, 2015
    9 years ago
  • Date Issued
    Tuesday, July 18, 2017
    7 years ago
Abstract
The present disclosure relates to an oral, immediate release, abuse deterrent liquid filled capsule containing polyethylene glycol and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is abuse deterrent to parenteral administration. The present disclosure also relates to processes of preparing the dosage form.
Description
FIELD OF THE TECHNOLOGY

The present disclosure relates to an oral immediate release, abuse deterrent dosage form. The dosage form contains polyethylene glycol (PEG) to reduce abuse by non-oral administration routes, e.g. intranasal and/or intravenous. The composition of PEG is designed to allow for immediate release of the active ingredient while deterring abuse and maintaining stability of the dosage form at elevated temperatures.


BACKGROUND

FDA-approved drugs are provided in many different forms based on the type of active substance, the indication treated and the preferred route of administration. These forms include enteral formulations (e.g., tablets, capsules or pills), parenteral formulations (e.g., injectable formulations such as intravenous, subcutaneous, intramuscular and intraarticular), liquid formulations (e.g., elixirs), lyophilized formulations and topical formulations. A majority of the FDA-approved drugs are currently available in enteral form, as either a tablet or capsule.


Several formulations have been investigated for deterring abuse, either by oral ingestion of the drug with alcohol, or by non-oral administration routes such as intranasal and/or intravenous administration. For example, U.S. 2014/0010873 (assigned to Egalet Ltd.) is directed to an abuse-deterrent pharmaceutical composition including at least one polyethylene oxide and at least one plasticizer. The polyethylene oxide has an average molecular weight of at least 1,000,000 Daltons, and the pharmaceutical composition includes at least 5 percent w/w of the at least one plasticizer. The pharmaceutical composition is designed to prevent immediate release of the at least one active drug substance after physical tampering. U.S. 2009/0123386 (assigned to MW Encap Limited) is directed to an abuse deterrent capsule including at least one modifier selected to prevent abuse. The modifier may have a high melting point or be insoluble in aqueous solvents or ethanol. For example, the high melting point excipient may be Poloxamer 188 or PEG 8000. U.S. 2010/0204259 (assigned to Egalet A/S) is directed to immediate release pharmaceutical compositions that are resistant to abuse by intake of alcohol. The release of the drug substance from the immediate release composition is decreased when the composition is exposed to a dissolution medium that includes ethanol. The compositions may be formulated to include at least one polyglycol and at least one effervescent agent.


SUMMARY

The present disclosure relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse, a first polyethylene glycol (PEG) having an average molecular weight between about 30,000 Daltons and about 40,000 Daltons; and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons. The ratio of the first PEG to the second PEG is less than about 1:4 w/w.


In some embodiments, the first PEG and the second PEG together are at least about 60 wt % of the dosage form. In some embodiments, the active substance is hydrocodone bitartrate. In other embodiments, the active substance is oxycodone hydrochloride (HCl). In some embodiments the capsule includes a grey dye including FD&C Blue #1, FD&C Yellow #6, and FD&C Red #40. In certain embodiments, the dye reduces abuse by providing a visual deterrent to injecting. In certain embodiments, about 60%, 70% 75%, 80%. 85% or about 90% or more of the capsule fill contents are soluble in both water and/or alcohol, e.g., ethanol. In certain embodiments, the ratio of the first PEG to the second PEG is between about 1:7 w/w and about 1:11 w/w. In some embodiments, the first PEG has an average molecular weight of about 35,000 Daltons and the second PEG has an average molecular weight of about 3350 Daltons. In some embodiments, the capsule includes at least about 2.5 wt % of the active substance. The capsule may be prepared by filling a capsule body with a heated homogenized suspension including the active substance, the first PEG and the second PEG.


The present disclosure also relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse and polyethylene glycol with a weighted average molecular weight between about 6200 Daltons and about 7800 Daltons. In certain embodiments, the capsule includes at least about 60 wt % of PEG. In some embodiments, the active substance is hydrocodone bitartrate. In other embodiments, the active substance is oxycodone HCl.


The present disclosure also relates to an immediate release, abuse deterrent capsule including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60° C., and a second PEG having a melting point less than or equal to about 57° C. The contents of the capsule can be solid at 40° C./75% relative humidity. In some embodiments, at least 90% of the active ingredient can be released from the capsule within 30 minutes following administration or via dissolution testing. In other embodiments, at least 75% of the active ingredients can be released from the capsule within 45 minutes following administration or via dissolution testing. In some embodiments, the first PEG and the second PEG together are at least about 60 wt % of the capsule. In particular embodiments, the active substance is hydrocodone bitartrate. In other embodiments, the active substance is oxycodone HCl.


The present disclosure also relates to a process for the production of an immediate release, abuse deterrent capsule including at least one active substance susceptible to abuse including preparing a homogenized suspension of the at least one active substance susceptible to abuse, a first PEG having an average molecular weight between about 30,000 Daltons and about 40,000 Daltons, and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons. The process can further include filling the homogenized suspension into a capsule body to produce an encapsulated dosage form. The ratio of the first PEG to the second PEG can be less than about 1:4 w/w, e.g., between about 1:7 w/w and about 1:11 w/w.


In certain embodiments of the aforementioned process, the first PEG and the second PEG together can be at least about 60 wt % of the capsule. In particular embodiments, the active substance is hydrocodone bitartrate. In other embodiments, the active substance is oxycodone HCl. In certain embodiments the capsule can be formed by joining a capsule body with a capsule cap.


The present disclosure also relates to a method of treating pain including administering to a subject in need thereof a therapeutically effective amount of any of the aforementioned capsules.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other advantages provided by the present disclosure will be more fully understood from the following description of exemplary embodiments when read together with the accompanying drawings, in which:



FIG. 1 shows cross sections of a capsule filling machine including the body segment, the cap disc, the hopper, the pumping box, the substation roller, and capsule bodies.



FIG. 2A shows solutions of grey dye before filtering. FIG. 2B shows solutions of grey dye after filtering.



FIG. 3 shows a summary of an exemplary manufacturing process for formulations of the present disclosure.



FIG. 4 shows unfiltered solutions of the dosage forms in 190 proof ethanol after shaking at 250 rpm for 3 hours.



FIG. 5 shows syringe-filtered solutions of the dosage forms in 190 proof ethanol after shaking at 250 rpm for 3 hours.





DETAILED DESCRIPTION

Abuse of prescription drugs, particularly opioids, is a serious and growing public health concern. To address this concern, new formulations are being developed that contain abuse-deterrent properties. Abuse deterrent properties include properties that make product manipulation more difficult or make abuse of the manipulated product less attractive or rewarding.


Recently the FDA issued a draft guidance for industry related to formulations having abuse deterrent properties. Guidance for Industry: Abuse Deterrent Opioids—Evaluation and Labeling, U.S. Department of Health and Human Services, FDA, CDER, January 2013, the entire contents of which are incorporated herein by reference. These guidelines separate abuse deterrent formulations into six categories, including: physical/chemical barriers, agonist/antagonist combinations, aversion, delivery system, prodrug, or a combination of the aforementioned. As described by the FDA guidance, the categories are:


Physical/Chemical barriers—Physical barriers can prevent chewing, pulverizing, cutting, grating, or grinding. Chemical barriers can resist extraction of the opioid using common solvents like water, alcohol, or other organic solvents. Physical and chemical barriers can change the physical form of an oral drug rendering it less amenable to abuse.


Agonist/Antagonist combinations—An opioid antagonist can be added to interfere with, reduce, or defeat the euphoria associated with abuse. The antagonist can be sequestered and released only upon manipulation of the product. For example, a drug product may be formulated such that the substance that acts as an antagonist is not clinically active when the product is swallowed but becomes active if the product is crushed and injected or snorted.


Aversion—Substances can be combined to produce an unpleasant effect if the dosage form is manipulated prior to ingestion or a higher dosage than directed is used.


Delivery System (including depot injectable formulations and implants)—Certain drug release designs or the method of drug delivery can offer resistance to abuse. For example, a sustained-release depot injectable formulation that is administered intramuscularly or a subcutaneous implant can be more difficult to manipulate.


Prodrug—A prodrug that lacks opioid activity until transformed in the gastrointestinal tract can be unattractive for intravenous injection or intranasal routes of abuse.


Combination—Two or more of the above methods can be combined to deter abuse.


An opioid analgesic submitted for abuse deterrent formulation (ADF) labeling must show conformance to one or more of these categories. The present disclosure relates to an abuse deterrent dosage form for oral administration, which provides immediate release of an active pharmaceutical substance and conforms to one or more of these categories. In one embodiment, the abuse deterrent dosage form of the present disclosure conforms to at least one of the six FDA categories. In another embodiment, the abuse deterrent dosage form of the present disclosure conforms to at least two of the six FDA categories. In another embodiment, the abuse deterrent dosage form of the present disclosure conforms to at least three of the six FDA categories. In another embodiment, the abuse deterrent dosage form of the present disclosure conforms to at least four of the six FDA categories. In another embodiment, the abuse deterrent dosage form of the present disclosure conforms to at least five of the six FDA categories.


For example, an abuse deterrent dosage form of the present disclosure can reduce abuse by the incorporation of at least one physical barrier. The physical barrier is designed to prevent abuse based on chewing, pulverizing, cutting, grating or grinding. Preferably, the physical barrier prevents or reduces the effectiveness of these methods. As used herein, the phrase “abuse deterrent” means that the active substance cannot readily be separated from the formulation in a form suitable for abuse by such means as, for example, grinding. The abuse deterrent form of the present disclosure cannot be easily ground, extracted from, or both. Abuse deterrent measures render it difficult to transform the dosage form into a residue or extract for non-oral administration, such as intranasal or intravenous.


In one embodiment, the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having an average molecular weight between about 30.000 Daltons and about 40,000 Daltons, and a second PEG having an average molecular weight between about 3000 Daltons and about 4000 Daltons. The ratio of the first PEG to the second PEG can be less than about 1:4 w/w. The wt % of active substance in the formulation may also vary depending on the active substance of the dosage form. In some embodiments, the dosage form includes at least about 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.8 wt %, 0.9 wt %, 1.0 wt %, 1.1 wt %, 1.2 wt %, 1.3 wt %, 1.4 wt %, 1.5 wt %, 2 wt %, 2.5 wt %, 3 wt %, 4 wt %, 5 wt %, 6 wt %, 7 wt %, 7.5 wt %, 8 wt %, 9 wt %, 10 wt %, 11 wt %, 12 wt %, 13 wt %, 14 wt %, 15 wt %, 16 wt %, 17 wt %, 18 wt %, 19 wt %, 20 wt %. 21 wt %, 22 wt %, 23 wt %, 24 wt %, 25 wt %, 26 wt %, 27 wt %, 28 wt %, 29 wt %, 30 wt %, 31 wt %, 32 wt %, 33 wt %, 34 wt %, 35 wt %, 36 wt %, 37 wt %, 38 wt %, 39 wt %, 40 wt %, 41 wt %, 42 wt %, 43 wt %, 44 wt %, 45 wt %, 46 wt %, 47 wt %, 48 wt %, 49 wt %, 50 wt %, 51 wt %, 52 wt %, 53 wt %, 54 wt %, 55 wt %, 56 wt %, 57 wt %, 58 wt %, 59 wt %, 60 wt %, 65 wt %, 69 wt %, 70 wt %, 75 wt %, 80 wt %, 85 wt %, 88 wt %, 90 wt %, or 95 wt % of the active substance. Any of these values may be used to define a range for the wt % of the active substance depending on the application. For example, the amount of active substance in the dosage form may range from about 0.10 wt % to about 60 wt %. Particularly, the amount of active substance in the dosage form may range from about 0.1 wt % to about 1.5 wt %, from about 5 wt % to about 30 wt %, from about 15 wt % to about 20 wt %, from about 15 wt % to about 30 wt %, from about 40 wt % to about 60 wt %, from about 40 wt % to about 50 wt %, or from about 42 wt % to about 46 wt %.


For example, the dosage form may be a 100 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, or about 30 mg of active substance (e.g., oxycodone HCl). In other embodiments, the dosage form may be a 150 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, or about 45 mg of active substance (e.g., oxycodone HCl). In other embodiments, the dosage form may be a 200 mg capsule including about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, or about 60 mg of active substance (e.g., oxycodone HCl). In other embodiments, the dosage form may be a 700 mg capsule including about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg or about 100 mg of an active substance (e.g., hydrocodone bitartrate).


As used herein, the term “active” or “active substance” or “active substance susceptible to abuse” or “API” means any opioid or opioid related compound subject to potential abuse. The active substance may include, without limitation, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levophenacylmorphan, levorphanol, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbulphine, narceine, nicomorphine, norpipanone, opium, oxycodone, papvretum, pentazocine, phenadoxone, phenazocine, phenomorphan, phenoperidine, piminodine, propiram, propoxyphene, sufentanil, tilidine, tapentadol, and tramadol, and pharmaceutically acceptable salts and mixtures thereof. For example, in some embodiments the active can be oxycodone HCl or hydrocodone bitartrate. In the dosage forms of the present disclosure, the active substance is not oxymorphone.


In particular, the active substance can be hydrocodone bitartrate or oxycodone HCl. The dosage form of the present disclosure can be rendered abuse deterrent by incorporating PEG in the dosage form. The PEG can deter abuse by preventing at least 50%, or at least 75%, of the capsule weight from being ground to a particle size below 500 μm, such as after 30 seconds of milling at 10,000 RPM. PEG can also prevent extraction of the active substance from the dosage form using an alcohol. Abusers can use the partial solubility characteristics of dosage form excipients to extract the active substance using alcohol and subsequently burn off the alcohol to form a purer residue containing the active substance. The inclusion of PEG in the formulation can prevent or reduce extraction because PEG can melt and form a wax before the alcohol can be completely evaporated or flashed off, an abuser may not be able to obtain a residue containing the active substance. Addition of a dye to the dosage form can also result in a colored solution after extraction of the active substance, deterring intravenous injection. By selecting the appropriate average molecular weight and quantity of PEG present within a dosage form, the characteristics of the dosage form can be manipulated in a way to create a wide array of abuse deterrent capsules having immediate release profiles.


Inclusion of PEG in the dosage form can result in the inability of the dosage form, e.g., capsule, to be abused by pulverizing and snorting, pulverizing and injecting, or combinations thereof. For example, the abuse deterrent dosage form of the present disclosure may be incapable of being significantly pulverized by physical or mechanical force due at least in part to the waxy characteristics of the PEG.


One of the most common means of abuse of an orally administered opioid analgesic involves the manipulation of the oral dosage form in order to cause rapid delivery to the bloodstream via nasal insufflation. In order for insufflation to be used as an effective means of abuse, the original dosage form must be manipulated so as to decrease the particle size of the ingested drug to about 500 μm or less. A particle size of about 500 μm or less is necessary for effective intranasal absorption to occur. By limiting the quantity of particles under about 500 μm that an abuser can obtain by reasonable methods, one can render insufflation ineffective as a means of abuse. Thus one way to prevent abuse by nasal insufflation is by capturing the active substance susceptible to abuse in a matrix which is resistant to being physically broken down to produce particles smaller than about 500 μm.


The dosage form of the present disclosure can inhibit manipulation by grinding or pulverizing using common equipment, such as a coffee grinder. For example, the formulation can deter abuse by limiting the particle size to which the formulation may be ground. The formulation prevents the dosage form, or at least substantial portions of the dosage from, from being ground in particles having a particle size of about 500 μm or less that may pass through the mucus membranes of the nasal cavity. The dosage form can also significantly limit the extraction of the active substance by common solvents (e.g., cold water or distilled aqueous ethanol) from the formulation. For example, the formulation deters abuse by limiting the ability of persons to extract the active substance from the formulation (either intentionally or unintentionally), such that the active substance cannot easily be concentrated for parenteral administration. The abuse deterrent dosage form may also include, but does not require, the incorporation of other deterrents such as antagonists or irritants.


For example, in one embodiment, the abuse deterrent can work as follows. If the dosage form is extracted with alcohol or an aqueous solution, the PEG and/or dye will also be extracted and cannot easily be separated from the active substance, preventing the preparation of pure drug for intravenous administration. Extraction with a solution would result in a grey/black liquid containing the PEG, dye and active substance. The inclusion of PEG in the formulation can prevent or reduce extraction because PEG can melt and form a wax before the alcohol can be completely evaporated or flashed off, an abuser may not be able to obtain a residue containing the active substance. These properties can allow for an oral drug delivery system that satisfies at least one of the categories in the FDA guidance (e.g., “physical and chemical barriers can change the physical form of an oral drug rendering it less amenable to abuse”).


The PEG can be capable of allowing immediate release of the active substance, providing abuse deterrence, and/or ensuring the formation of a solid dosage form that is stable at elevated temperatures, for example 40° C. In some embodiments, the PEG provides all three. The dosage form of the present disclosure can accomplish the above capabilities by using a mixture of PEG molecules of at least two different average molecular weights. For example, the dosage form may include a first PEG having an average molecular weight between about 30,000 Daltons and 40,000 Daltons, and a second PEG having an average molecular weight about 3000 Daltons and 4000 Daltons.


In some embodiments, the first PEG has an average molecular weight of about 20, 000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 30,500, 31,000, 31,500, 32,000, 32,500, 33,000, 33,500, 34,000, 34,500, 35,000, 35,500, 36,000, 36,500, 37,000, 37,500, 38,000, 38,500, 39,000, 39,500 or 40,000 Daltons. Any of these values may be used to define a range for the average molecular weight of the first PEG. For example, the first PEG can have an average molecular weight between about 31,000 Daltons and about 39,000 Daltons, between about 32,000 Daltons and about 38,000 Daltons, between about 33,000 Daltons and about 37,000 Daltons, between about 34,000 Daltons and about 36,000 Daltons, between about 30,000 Daltons and about 32,000 Daltons, between about 32,000 Daltons and about 34,000 Daltons, between about 36,000 Daltons and about 38,000 Daltons, or between about 38,000 Daltons and about 40,000 Daltons.


In some embodiments, the second PEG can have an average molecular weight of 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950 or 4000 Daltons. Any of these values may be used to define a range for the average molecular weight of the second PEG. For example, the second PEG can have an average molecular weight between about 3100 Daltons and about 3900 Daltons, between about 3200 Daltons and about 3800 Daltons, between about 3300 Daltons and about 3700 Daltons, between about 3400 Daltons and about 3600 Daltons, between about 3000 Daltons and 3200 Daltons, between about 3200 Daltons and about 3400 Daltons, between about 3600 Daltons and about 3800 Daltons, or between about 3800 Daltons and about 4000 Daltons.


In some embodiments, the ratio of the first PEG to the second PEG can be about 3:1, 2:1, 1:1, 1:2, 1:3,1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19 or 1:20. Any of these values may be used to define a range for the ratio of the first PEG to the second PEG. For example, in some embodiments, the ratio of the first PEG to the second PEG can be between about 1:2 w/w and about 2:1 w/w, between about 1:3 w/w and about 1:1 w/w, between about 1:2 w/w and about 1:1 w/w, between about 1:1 w/w and about 2:1 w/w, between about 1:1 w/w and about 3:1 w/w, between about 1:4 w/w and about 1:10 w/w, between about 1:7 w/w and about 1:11 w/w, or between about 1:8 w/w and about 1:10 w/w. In other embodiments, the ratio of the first PEG to the second PEG can be less than about 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19 or 1:20. For example, a ratio of 1:10 is less than a ratio of 1:9.


The total wt % of PEG in the dosage form may vary depending on the active substance, stability, and release profile. In some embodiments, the first PEG and the second PEG together are at least about 5 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, 35 wt %, 36 wt %, 37 wt %, 38 wt %, 39 wt %, 40 wt %, 41 wt %, 42 wt %, 43 wt %, 44 wt %. 45 wt %, 46 wt %, 47 wt %, 48 wt %, 49 wt %, 50 wt %, 51 wt %, 52 wt %, 53 wt %, 54 wt %, 55 wt %, 56 wt %, 57 wt %, 58 wt %, 59 wt %, 60 wt %, 61 wt %, 62 wt %, 63 wt %, 64 wt %, 65 wt %, 66 wt %, 67 wt %, 68 wt %, 69 wt %, 69.7 wt %, 70 wt %, 71 wt %, 72 wt %, 73 wt %, 74 wt %, 75 wt %, 76 wt %, 77 wt %, 78 wt %, 79 wt %, 80 wt %, 85 wt %, 88 wt %, 90 wt %, or 95 wt % of the dosage form.


In one embodiment, the formulation includes a disintegrant. A disintegrant promotes disintegration of the capsule, and dissolution of the active substance, after administration and upon contact with water. The disintegrant may be selected from sodium starch glycolate, cross-linked polyvinylpyrrolidone (e.g. crospovidone), cross-linked sodium carboxymethylcellulose (e.g. croscarmellose sodium) sodium bicarbonate/citric acid, alginic acid or combinations thereof. In particular embodiments, the disintegrant is selected from sodium starch glycolate, crospovidone and croscarmellose. The dosage form may contain about 1 wt %, 2 wt %, 3 wt %, 4 wt %, 5 wt %, 6 wt %, 7 wt %, 8 wt %, 9 wt %, 10 wt %, 11 wt %, 12 wt %, 13 wt %, 14 wt %, 15 wt %, 16 wt %, 17 wt %, 18 wt %, 19 wt % or 20 wt % of disintegrant. Any of these values may be used to define a range for the wt % of disintegrant. For example, the dosage form may contain between about 1.0 wt % and about 20 wt % of disintegrant. Particularly, the formulation may contain between about 1.0 wt % and about 10 wt % disintegrant or between about 5 wt % and about 8 wt % disintegrant. In certain embodiments, the dosage form includes 5 wt % sodium starch glycolate, 8 wt % sodium starch glycolate, 5 wt % crospovidone, or 5 wt % croscarmellose sodium. In another embodiment, the dosage form of the present disclosure excludes a disintegrant.


In some embodiments, the formulation includes a dye. A dye can be useful in deterring abuse by discouraging the abuser from intravenous injection. For example, extraction of the dye along with the active ingredient would result in a colored solution that would discourage the abuser from intravenous injection. Thus, in certain embodiments, the dye reduces abuse by extracting and injecting. The dye may be selected from known dyes suitable for use in pharmaceutical formulations or approved by the FDA for such use. For example, the dye may be FD&C Blue No. 2 or a 50/50 wt % solution of FD&C Blue No. 2 in PEG. In another embodiment, the dye may be a grey dye including FD&C Blue #1, FD&C Yellow #6, and FD&C Red #40. The dye may be in a 90% PEG 3350 blend. In certain embodiments, 14 mg of dye blend can be used in each capsule or about IA: mg of concentrated dye. In certain embodiments a grey dye is used since it is visually deterring and non-transparent. The dosage form may include about 0.10 wt %, 0.20 wt %, 0.30 wt %, 0.40 wt %, 0.50 wt %, 1 wt %, 2 wt %, 3 wt %, 4 wt %, 5 wt %, 6 wt %, 7 wt %, 8 wt %, 9 wt %, 10 wt %, 11 wt %, 12 wt %, 13 wt %, 14 wt %, 15 wt %, 16 wt %, 17 wt %, 18 wt %, 19 wt %, or 20 wt % dye. Any of these values may be used to define a range for the wt % of the dye. For example, the dosage form may contain between about 0.10 wt % and about 15 wt % dye. Particularly, the dosage form may contain between about 0.20 wt % and about 1.5 wt % dye, about 0.50 wt % and about 1.0 wt % dye, or about 7 to about 14 wt % dye. In certain embodiments, the dosage form may include about 1 mg, 1.4 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg or 30 mg of dye. In another embodiment, the dosage form of the present disclosure excludes a dye.


In some embodiments, the dosage form includes a first dye and a second dye, wherein the first dye has a high solubility in aqueous solution that is higher than the solubility of the second dye in aqueous solution. For example, in some embodiments the first dye has a solubility in aqueous solution of about 1 g, 5 g, 10 g, 30 g, 50 g, 100 g or 500 g in 1 L of aqueous solution and the second dye has a solubility in aqueous solution of about 1 mg, 5 mg, 10 mg, 30 mg, 50 mg, 100 mg, 500 mg, 1 g, or 10 g in 1 L of aqueous solution. In some embodiments, the second dye has a high solubility in non-aqueous solution that is greater than the solubility of the first dye in non-aqueous solution. For example, in some embodiments, the first dye has a solubility in non-aqueous solution of about 1 mg, 5 mg, 10 mg, 30 mg, 50 mg, 100 mg, 500 mg, 1 g, or 10 g in 1 L of non-aqueous solution, and the second dye has a solubility in non-aqueous solution of about 1 g, 5 g, 10 g, 30 g, 50 g, 100 g or 500 g in 1 L of non-aqueous solution. In some embodiments, the color of the first dye is substantially the same as the color of the second dye. In other embodiments, the color of the first dye is substantially different from the color of the second dye. For the purposes of the present disclosure, a dye is considered to be soluble in a solvent if about 1 g of the dye can be dissolved in about 10-30 mL of the solvent. For example, a dye is considered to be water soluble if about 1 g of the dye can be dissolved in 10-30 mL of water.


In another embodiment, the dosage form includes a preservative or antioxidant. The preservative or antioxidant can reduce or limit the degradation or deterioration of the abuse deterrent dosage form. For example, the components of the oral drug delivery system (e.g., active substances, PEG) may undergo degradation (e.g., oxidative reduction, chain cleavage) due to oxidation. Preventing degradation can help maintain the abuse deterrent properties of the formulation. For instance, the molecular weight of PEG in the formulation affects the resistance to grinding, for example, with a coffee grinder. The addition of a preservative or antioxidant in the formulation that reduces or eliminates the degradation of the molecular weight of PEG may be useful in maintaining the abuse deterrence properties of the dosage form. In addition to maintaining abuse deterrence, the addition of a preservative or antioxidant in the dosage form may be necessary to prevent premature degradation of the active substance over the shelf life of the dosage form.


The preservative or antioxidant may be selected from preservatives or antioxidants known to one skilled in the art for use in pharmaceutical formulations, such as citric acid, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), erythorbic acid, hypophosphorous acid, lactobionic acid, monothioglycerol, potassium metabisulfite, propyl gallate, racemethionine, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, stannous chloride, sulfur dioxide and tocopherols. The formulation, or dosage form, may contain between about 0.1 wt % and about 2.0 wt %, or about 0.25 wt % and about 0.75 wt % of preservative or antioxidant. In another embodiment, the dosage form of the present disclosure excludes a preservative or antioxidant.


In some embodiments, the dosage form includes one or more excipients that form a gel in the presence of an alcohol. The alcohol gelling/thickening agent reduces or limits the potential for abuse by preventing extraction of the active substance from the dosage form. For example, when introduced to an alcohol solution, the components of the dosage form (e.g., active substances, PEG) may become trapped in a gel/viscous liquid which prevents extraction and subsequent alcohol evaporation to produce a pure active substance. In one embodiment, the alcohol gelling/thickening agent does not form a gel in the presence of water. The dosage form can contain up to about 1%, 2%, 3%, 4%, 5%, 6%. 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39% or about 40%. These values can be used to define a range, such as about 0.1 wt % to about 40 wt % alcoholic gelling/thickening agent. In another embodiment, the dosage form of the present disclosure does not contain an alcohol gelling/thickening agent.


The alcohol gelling/thickening agent may be a gelling or thickening agent known to one skilled in the art for use in pharmaceutical formulations, such as acacia, alginic acid, bentonite, calcium acetate, carbomers, carboxymethylcellulose, ethylcellulose, gelatin, hydroxyethylcellulose, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, poloxamers, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sodium alginate, sorbitol derivatives, tragacanth, or xanthan gum.


The dosage form may additionally include at least one additive independently selected from surfactants, bulking agents, lubricants, flavorings or combination thereof.


The abuse deterrent dosage form of the present disclosure is capable of immediate release of the active substance. The dosage form may be manufactured to provide a composition exhibiting an immediate release profile of at least one active substance. As used herein, “immediate release” refers to a dosage form that releases the active substance or a pharmaceutically acceptable salt thereof, e.g., oxycodone HCl or hydrocodone bitartrate, substantially completely into the gastrointestinal tract of the user within a period of less than an hour, and often less than about 45 minutes or 30 minutes from ingestion. In one embodiment, the amount of active substance released from the dosage form, e.g., oxycodone HCl or hydrocodone bitartrate, by exposure to deaerated water within 45 minutes is greater than or equal to 75%. In another embodiment, the amount of active substance released from the dosage form, e.g., hydrocodone bitartrate, by exposure to a 0.1 N hydrochloric acid solution within 30 minutes is greater than or equal to 90%. In other embodiment, the amount of active substance released from the dosage form, e.g., oxycodone HCl, within 45 minutes is greater than or equal to 75%.


In one embodiment, the dosage form of the present disclosure releases greater than or equal to about 75% of the active substance within 45 minutes after administration or via dissolution testing. Particularly, the dosage form releases greater than or equal to about 80%, about 85%, about 90%, or about 95% of the active substance within 45 minutes after administration or via dissolution testing.


In other embodiments, the dosage form of the present disclosure releases greater than or equal to about 90% of the active substance within 30 minutes after administration or via dissolution testing. Particularly, the dosage form releases greater than or equal to about 92%, about 94%, about 96%, or about 98% of the active substance within 30 minutes after administration or via dissolution testing.


The present disclosure also relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse and PEG with a weighted average molecular weight between about 6200 Daltons and about 7800 Daltons. In one embodiment, dosage forms containing an average molecular weight of PEG in this particular range have several desirable characteristics including immediate release of the active substance, stability at high temperature conditions (e.g., 40° C. with 75% relative humidity), relatively low viscosity at elevated temperatures (e.g., a viscosity less than or equal to 2000 cP at 75° C.), and/or a relatively high particle size after grinding (e.g., greater than or equal to 50% of the particles having a diameter greater than or equal to 500 μm after grinding, such as for 30 seconds at 10,000 RPM). Dosage forms including PEG with an average molecular weight between about 6200 Daltons and about 7800 Daltons may be prepared by combining two or more PEGs with different molecular weights. For example, any of the PEGs described herein (e.g., PEG 3350 and PEG 35000) may be combined to prepare a dosage form including PEG with an average molecular weight range between about 6200 Daltons and about 7800 Daltons.


In particular embodiments, the dosage form includes PEG, or two or more PEGs, with an average molecular weight of about 5000, 5015, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6515, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10,000, 10,100, 10,200, 10,300, 10,400, 10,500, 10,600, 10,700, 10,800, 10,900, 11,000, 11,100, 11,200, 11,300, 11,400, 11,500, 11,600, 11,675, or 11,700 Daltons. Any of these values may be used to define a range of average molecular weights for PEG, or PEGs, depending on the application. For example, in some embodiments, the dosage form includes PEG, or PEGs, with an average molecular weight between about 6200 Daltons and about 6515 Daltons, between about 6515 Daltons and about 6800 Daltons, or between about 6200 Daltons and about 6800 Daltons.


In other embodiments, the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60° C. and a second PEG having a melting point less than or equal to about 57° C. The dosage form can be a solid at 40° C./75% relative humidity, and at least 90% of the active ingredient can be released from the dosage form within 30 minutes following administration or via dissolution testing. The dosage form can be a solid at 40° C./75% relative humidity, and at least 75% of the active ingredient can be released from the dosage form within 45 minutes following administration or via dissolution testing.


The melting point of PEG can be positively correlated with molecular weight, i.e. higher molecular weight PEGs have higher melting points. For example, PEGs with an average molecular weight up to 400 Daltons can be considered nonvolatile liquids at room temperature. PEG 600, for example, has a melting range of about 17 to 22° C., and may be liquid at room temperature but waxy at lower temperatures. PEGs with an average molecular weight of 800 to 2000 Daltons can be considered waxy materials at room temperature with a relatively low melting range. For example, PEG 1500 has a melting point of about 42-46° C. PEGs with an average molecular weight above 3000 can be considered solids. For example, PEG 3350 has a melting point of about 53-57° C., and PEG 35,000 has a melting point of about 60-65° C. By combining a PEG with a relatively low melting point (e.g., PEG 3350) with a PEG with a relatively high melting point (e.g., PEG 35,000) a dosage form with several desirable properties can be formed, including immediate release of an active substance, stability at high temperatures (e.g., 40° C. with 75% relative humidity), relatively low viscosity at elevated temperatures (e.g., less than or equal to 2000 cP at 75° C.), and/or a relatively high particle size after grinding (e.g., greater than or equal to 50% of the particles having a diameter greater than or equal to 500 μm) and/or the incorporation of a chemical barrier which makes it difficult to separate the active substance from the rest of the formulation.


In some embodiments, the dosage form includes a first PEG having a melting temperature greater than or equal to about 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C. 69° C., or 70° C. Any of these values may be used to define a range of melting temperatures for the first PEG depending on the application. For example, the dosage form may include a first PEG having a melting temperature from about 52° C. to about 60° C., from about 55° C. to about 60° C., from about 53° C. to about 57° C., from about 53° C. to about 56° C., from about 55° C. to about 58° C., from about 60° C. to about 65° C., or from about 60° C. to about 70° C.


In some embodiments, the dosage form includes a second PEG having a melting temperature less than or equal to about 5° C., 10° C., 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 25° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 55° C., 56° C., or about 57° C. Any of these values may be used to define a range of melting temperatures for the second PEG depending on the application. For example, the dosage form may include a second PEG having a melting temperature between about 17° C. and about 22° C. between about 42° C. and about 46° C., between about 53° C. and about 57° C., or between about 42° C. and about 57° C.


In some embodiments, the dosage form includes a first PEG and a second PEG, wherein the first PEG and the second PEG combined have a melting temperature of about 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C. Any of these values may be used to define a range of melting temperatures for the combined first and second PEG depending on the application. For example, the first PEG and the second PEG combined may have a melting temperature between about 53° C. and about 65° C.


In other embodiments, the present disclosure relates to an oral, immediate release, abuse deterrent dosage form including an active substance susceptible to abuse, a first PEG having a melting point greater than or equal to about 60° C. and a second PEG having a viscosity at 100° C. less than or equal to about 110 cSt. The dosage form can be a solid at 40° C./75% relative humidity, and at least 75% of the active ingredient can be released from the dosage form within 45 minutes following administration or via dissolution testing or at least 90% of the active ingredient can be released from the dosage form within 30 minutes following administration or via dissolution testing.


In some embodiments, the dosage form includes a second PEG having a viscosity at 100° C. of less than or equal to about 500 cSt, 450 cSt, 400 cSt, 350 cSt, 300 cSt, 250 cSt, 200 cSt, 190 cSt, 180 cSt, 170 cSt, 160 cSt, 158 cSt, 150 cSt, 140 cSt, 130 cSt, 123 cSt, 120 cSt, 110 cSt, 105 cSt, 100 cSt, 99 cSt, 93 cSt, 90 cSt, 87 cSt, 80 cSt, 76 cSt, 75 cSt, 73 cSt, 70 cSt, 67 cSt, 60 cSt, 50 cSt, 49 cSt, 48 cSt, 47 cSt, 46 cSt, 45 cSt, 44 cSt, 43 cSt, 42 cSt, 41 cSt, 40 cSt, 39 cSt, 38 cSt, 37 cSt 36 cSt, 35 cSt, 34 cSt, 33 cSt, 32 cSt, 31 cSt, 30 cSt, 29 cSt, 28 cSt, 27 cSt, 26 cSt, 25 cSt, 24 cSt, 23 cSt, 22 cSt, 21 cSt, 20 cSt, 19 cSt, 18 cSt, 17 cSt, 16 cSt, 15 cSt, 14 cSt, 13 cSt, 12 cSt, 1 J cSt, 10 cSt, 9 cSt, 8 cSt, 7 cSt, 6 cSt, 5 cSt, or about 4 cSt. Any of these values may be used to define a range of viscosities for the second PEG depending on the application. For example, the dosage form may include a second PEG having a viscosity between about 4.0 cSt and about 49.0 cSt, between about 16.0 cSt and about 49.0 cSt, between about 25.0 cSt and about 32.0 cSt, or between about 76 cSt and about 110 cSt.


In some embodiments, the formulation of the present disclosure can have a viscosity at 100° C. of about 40 cSt, 41 cSt, 42 cSt, 43 cSt, 44 cSt, 45 cSt, 46 cSt, 47 cSt, 48 cSt, 49 cSt, 50 cSt, 51 cSt, 52 cSt, 53 cSt, 54 cSt, 55 cSt, 56 cSt, 57 cSt, 58 cSt, 59 cSt, 60 cSt, 61 cSt, 62 cSt, 63 cSt, 64 cSt, 65 cSt, 66 cSt, 67 cSt, 68 cSt, 69 cSt, 70 cSt, 71 cSt, 72 cSt, 73 cSt, 74 cSt, 75 cSt, 76 cSt, 77 cSt, 78 cSt, 80 cSt, 90 cSt, 100 cSt, 110 cSt, 120 cSt, 130 cSt, 140 cSt, 150 cSt, 158 cSt, 160 cSt, 170 cSt, 180 cSt, 190 cSt, 200 cSt, 250 cSt, 300 cSt, 350 cSt, 400 cSt, 450 cSt 500 cSt, 600 cSt, 700 cSt, 800 cSt, 900 cSt, 1000 cSt, 1100 cSt, 1200 cSt, 1300 cSt, 1400 cSt, 1500 cSt, 1600 cSt, 1700 cSt, 1800 cSt, 1900 cSt, or about 2000 cSt. Any of these values may be used to define a range of viscosities for the formulation of the present disclosure depending on the application. For example, the formulation of the present disclosure may have a viscosity between about 500 cSt and about 2000 cSt, or between about 800 cSt and about 1900 cSt. In some embodiments, the formulation or dosage form is a solid at room temperature and/or at 100° C. and has not measureable viscosity.


In another embodiment, the present disclosure relates to a process for the production of an oral, immediate release, abuse deterrent dosage form including preparing a homogenized suspension of at least one active substance susceptible to abuse, a first PEG, and a second PEG. For example, the first PEG can have an average molecular weight between about 30,000 Daltons and about 40,000 Daltons, and the second PEG can have an average molecular weight between about 3000 Daltons and about 4000 Daltons. The ratio of the first PEG to the second PEG can be less than about 1:4 w/w. The process can further include dispensing or filling a homogenized suspension into a capsule to produce the dosage form. In some embodiments, the capsule can be formed by joining a capsule body with a capsule cap. The first PEG and the second PEG together may be any wt % of the dosage form as described herein, for example at least about 60 wt % of the dosage form. In some embodiments of the processes described herein, the active substance is hydrocodone bitartrate. In other embodiments, the active substance is oxycodone HCl. In certain embodiments, the abuse deterrent dosage forms of the present disclosure are capsules.


The abuse deterrent dosage forms of the present disclosure may be produced by liquid filled encapsulation. Liquid filled encapsulation is a process in which active pharmaceutical ingredients are suspended or emulsified in a carrier matrix and filled into capsules. The capsules are usually made of hard gelatin or hydroxypropyl methylcellulose. One of the advantages of this dosage form is that it requires fewer excipients and processing steps than other traditional compressed solid dosage forms. The internal solid phase API (e.g., oxycodone HCl or hydrocodone bitartrate) can be suspended in a PEG external fluid phase. In one embodiment, PEGs with average molecular weights greater than about 1500 Daltons are ideal for liquid filled capsules because they are thermoplastics that melt at temperatures below the melting point of the hard gelatin capsule (<70° C.) and are solids at room temperature. If the filling material is liquid at room temperature, a banding process can be used. This process adds a gelatin band around the point where the capsule body and cap join to create a unified capsule body to prevent leakage. In some embodiments, the formulation of the present disclosure can include a band.


In one embodiment, the liquid fill process can begin by dispensing excipients (e.g., PEG and stabilizers/preservatives) and API according to theoretical percent weights of the final capsule fill weight. Following this step, the PEG powders or flakes and dyes are pre-melted before they are added to a homogenizing mixing kettle which can maintain the PEG above its melting point via jacketing on the kettle. When the PEG is completely fluid, the API and other non-melting stabilizers and/or preservatives can be mixed in to form a homogenized suspension. This can occur with the aid of mechanical agitation by way of several internal stirring arms. Once a homogenized suspension is attained (in some embodiments newer kettles can be equipped with NIR probes to indicate when this happens), the suspension can be pumped through jacketed hoses (to maintain the internal kettle temperature to prevent solidification in the hose) to a hopper on the capsule filling machine. An illustration of a capsule filling machine is provided in FIG. 1.


The capsule filling hopper can also be jacketed to heat the suspension to prevent solidification. The capsule filling machine can contain a separate hopper which operators fill with hard gelatin capsules. The hopper can feed into a rectifying drum which can align all capsules in the same direction. Once aligned, the capsules can sit vertically in a cap disk which can allow for separation of the body and cap via vacuum. To fill the capsule, a positive displacement piston pump can be used to draw the product in from the jacketed hopper and dispense the suspension into the capsule body through a set of changeable nozzles. Fill weight adjustment can be achieved by varying the piston stroke of the pump. These changes can be made throughout the process due to frequent in-process capsule weight checks.


Once the capsule body is filled, the capsule body and cap can be joined via pusher pins which raise the capsule body upwards and into the capsule cap, which are held in place above the capsule body by a joining block. The pusher pins can then push the unified capsule out of the cap disk and discharge them from the machine. The capsules can then be allowed to cool at room temperature on trays and can be each weight checked via a capsule weigh checking machine. Following this, the capsules can then be placed into a final output drum. Automatic capsule filling machines can have the ability to produce 500 to 150,000 capsules an hour with a very high degree of accuracy.


In some embodiments, the present disclosure relates to a dosage form as described herein prepared by filling a capsule body with a heated homogenized suspension including an active substance, a first PEG and a second PEG. In some embodiments, the homogenized suspension including an active substance, a first PEG, and a second PEG melts at a temperature of about 42° C., 43° C., 44° C., 45° C. 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C. 73° C., 74° C., or 75° C. Any of these values may be used to define a range of melting temperatures for the homogenized suspension. For example, in certain embodiments, the homogenized suspension has a melting temperature between about 53° C. and about 65° C. In particular embodiments, the homogenized suspension including an active substance, a first PEG and a second PEG melts at temperatures below 77° C., i.e., the melting point of the hard gelatin capsule. In another embodiment, the present disclosure relates to a method of treating pain including administering to an individual in need thereof a therapeutically effective amount of a dosage form as described herein. The dosage form can be used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. The dosage form can provide rapid onset of analgesia for the treatment of moderate to severe pain. The dosage form. e.g., a hard gelatin capsule, can be administered orally every 4-6 hours as needed.


The disclosures of all cited references including publications, patents, and patent applications are expressly incorporated herein by reference in their entirety. Further, when an amount, concentration, or other value or parameter is given as either a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. Where a range of numerical values is recited herein, unless otherwise stated, the range is intended to include the endpoints thereof, and all integers and fractions within the range. It is not intended that the scope of the invention be limited to the specific values recited when defining a range.


The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only.


EXAMPLES
Example 1

Initial testing and evaluation experiments for the immediate release ADF liquid filled capsule were based on suspending an API in PEG and filling it to weight into a hard gelatin capsule which then solidifies into a wax at room temperature. Some of these experiments used acetaminophen (APAP) as a tracer drug in place of C-II narcotics. Oxycodone HCl and APAP are both soluble in reaerated water. The USP monograph for pooled hydrocodone bitartrate and acetaminophen tablets specifies 80% (Q) +10% release of both drugs in 30 minutes in 0.1N HCl, indicating both are capable of immediate release. As a result, APAP was expected to be a viable alternative for experimentation.


A formulation was prepared containing 30 mg APAP and a 50:50 ratio of PEG 3350:1500 g/mol and 0.50% FD&C dye in size 3 white opaque capsules. Three capsule fill weights were evaluated: 100 mg, 150 mg, and 200 mg. These formulations were tested for dissolution. The USP criteria for immediate release of oxycodone HCl is 500 mL purified water as media, Q=70% at 45 minutes, Specification=75% (Q+5%), apparatus 2 (paddles), 50 rpm. All capsule weights proved to release immediately, with the 150 mg and 200 mg formulations releasing completely at 20 minutes. 100 mg capsule fill would be preferred to decrease material costs. Table 1 below list the dissociation data of size 3 capsules containing 30 mg APAP, a 50:50 ratio of PEG 3350:1500 g/mol, and 0.5% FD&C dye.














TABLE 1





Batch
Capsule fill
20 Minutes
Average
45 Minutes
Average




















18-1
100 mg
78.18
78.07
86.25
86.19


18-2

78.66

88.23



18-3

77.37

84.11



19-1
150 mg
92.76
95.48
96.95
95.17


19-2

98.55

100.69



19-3

95.13

87.86



20-1
200 mg
92.74
91.82
96.68
96.59


20-2

88.16

96.59



20-3

94.57

96.50









These dosage forms contain water-and ethanol-soluble FD&C dyes, e.g., 0.5% FD&C dye, to deter extraction of the API and intravenous injection of the solution. Further rendering of the drug solution would be required to separate the pure API from the PEG and FD&C dyes.


PEG 1450 (NF grade available from Dow Chemical Company) can be used in place of PEG 1500 in the oxycodone HCl dosage forms. Additional exemplary oxycodone HCl dosage forms are shown in Table 2 below. 1% citric acid may be used in the dosage forms as an API stabilizer.















TABLE 2








Oxyco-
PEG
PEG

Citric
Total



done
3350
1450
FD&C
Acid
Capsule Fill


Dosage
HCl (mg)
(mg)
(mg)
Dye (mg)
(mg)
(mg or %)





5
5
44.25
44.25
0.5
1
100


15
15
34.25
34.25
0.5
1
100


30
30
19.25
19.25
0.5
1
100






Oxyco-
PEG
PEG

Citric
Total



done
3350
1450
FD&C
Acid
Capsule Fill


Dosage
HCl (%)
(%)
(%)
Dye (%)
(%)
(mg or %)





5
5
41-47
41-47
0.25-0.75
0.5-2
100


15
15
31-37
31-37
0.25-0.75
0.5-2
100


30
30
16-22
16-22
0.25-0.75
0.5-2
100









Example 2
Immediate Release ADF Liquid Fill Capsules including PEG 35000

The dissolution rate, ADF properties and melt temperatures of additional immediate release ADF oxycodone HCl liquid fill capsule formulations containing varying amounts of PEG 1450 and PEG 35000 were evaluated. Acetaminophen (APAP) was used as a tracer drug for oxycodone HCl. The formulations are shown in Table 3 below. The target amount of APAP was 30 mg per capsule, and the target fill weight was 100 mg (batch number 92) or 200 mg (batch numbers 93-94). The capsules contained 30% w/w (batch number 92) or 15% w/w (batch numbers 93-94) APAP. Size 3 opaque hard gelatin capsules were used.


Dissolution was tested using the following criteria: Q=not less than 70% dissolved at 45 minutes, and the specification =Q+5% (75%) dissolved at 45 minutes. As shown in Table 3, the average dissolution for the three formulations ranged from 87% to 98%. Accordingly, all of the formulations met the specification of at least 75% dissolution at 45 minutes.


As mentioned above, it is generally accepted that any particle greater than 500 μm in diameter cannot be sufficiently absorbed by the blood vessels in the nasal mucosa. Thus, in one embodiment, a formulation is considered to deter intranasal abuse if ≧75% of the particles are ≧500 μm in diameter after grinding. As shown in Table 3, the percentage of particles ≧500 μm in diameter after grinding ranged from 90% to 92%. Thus all of the oxycodone formulations met the standard of ≧75% of the particles being ≧500 μm in diameter after grinding.









TABLE 3







Dissolution and Particle Size after Grinding for Oxycodone HCl


Formulations Including PEG 35000 and PEG 1450.












Excipients


Grinding/














%
% of
Dissolution
Particle Size














Batch
% PEG
PEG
Overall
% @ 45
Aver-
%
%


Number
35000
1450
Fill
min**
age
≧500 μm
<500 μm

















92-1
100
0
70
100
87
97
8


92-2



83





92-3



77





93-1
82
18
85
91
90
91
9


93-2



90





93-3



88





94-1
59
41

98
98
90
10


94-2



99





94-3



95









The oxycodone HCl formulations were also analyzed to determine melting temperature. The capsules were held at 40° C./75% relative humidity for 72 hours. As shown in Table 4 below, the batch number 92 and 93 formulations containing 100% and 82% PEG 35000, respectively, were solid at these conditions, while the batch number 94 formulation containing 59% PEG 35000 had a much softer fill.









TABLE 4







Melt study of Oxycodone HCl formulations.













%
%
% of




Batch
PEG
PEG
Overall




Number
1450
35000
Fill
Designation*
Notes















92
0
100
70
1
No evidence of melt


93
18
82
85
1
No evidence of melt


94
41
59

2
Much softer fill





*1 (one) = Solid, 5 (five) = Thick Liquid






The dissolution, particle size after grinding, and color extraction of two additional formulations of oxycodone HCl (batch numbers 11 and 12) containing varying percentages of PEG 35000 and PEG 1450 were determined as described above. The formulations also contained 1% citric acid and 14% Grey Dye. Both formulations used a size 3 opaque hard gelatin capsule with a target fill weight of 100 mg. APAP was used as a tracer drug for oxycodone HCl. The target amount of APAP was 5 mg (5% w/w) for batch number 11 and 30 mg (30% w/w) for batch number 12. For dissolution, Q=Not less than 70% dissolved at 45 minutes, and the specification =Q+5% (75%) dissolved at 45 minutes. As a reference, an acceptable particle size after grinding is ≧75% particles ≧500 μm in diameter. As a reference, an acceptable color scale designation after extraction of the dye is ≧4 on a scale of 1 to 5, with 5 being the highest level of color.


As shown in Table 5 below, both oxycodone HCl formulations met the criteria for dissolution rate, particle size after grinding, and color extraction.









TABLE 5







Dissolution, Particle Size after Grinding, and Color Extraction of Oxycodone HCl


Formulations containing PEG 35000 and PEG 1450.


Oxycodone HCl Formulation












Excipients

Grinding/

















%
%
%
%
% of
Dissolution
Particle Size
Extraction
















Batch
PEG
PEG
Citric
Grey
Overall
Avg. %
%
%
Color Scale


Number
35000
1450
Acid
Dye
Fill
@ 45 min
≧500 μm
<500 μm
Designation



















11-1
48
32
1
14
95
106
90
10
5


11-2











11-3











12-1
33
22


70
96
89
11
5


12-2











12-3









In one embodiment, hot melt fill capsules are sufficiently viscous at elevated temperatures to allow for flow of the fill into the capsules. Accordingly, additional oxycodone HCl formulations containing PEG 35000 and either PEG 3350 or PEG 1450 were evaluated by measuring viscosity at 75° C. at 50 rpm. Formulations were weighed out according to total wt % of a 15 g batch. Each formulation was poured into a viscosity testing crucible and placed in an 80° C. water bath to melt. Once fully melted, the formulations were mixed using a stainless steel spatula and transferred to a Brookfield DV-II+ Pro Viscometer (VIS29 NCD: Upon Use) utilizing Spindle: S27 (Small Sample Adapter). The viscometer was equipped with a water jacketed crucible platform. Once the melt temperature reached 75° C., a viscosity reading was taken in centipoise (cP). Based on manufacturer specifications, an acceptable viscosity for the purposes of this study is ≦1000 cP. The particle size after grinding and stability at 40° C./75% relative humidity (RH) was also determined. For the grinding analysis, an acceptable particle size after grinding was considered to be ≧75% particles ≧500 μm in diameter. All formulations were size 3 opaque hard gelatin capsules.


As shown in Table 6 below, batch number 100 containing 11% PEG 35000 and 44% PEG 1450 had a viscosity of 1288 cP at 75° C./50 rpm, above the manufacturer specification of ≦1000 cP. Accordingly, viscosity was not measured for the formulations containing higher percentages of PEG 35000 (i.e. batch numbers 97-99). In addition, batch number 100 was not sufficiently stable for storage, since this formulation was a very viscous liquid at the stability test conditions of 40° C./75% RH.


Although batch number 101 containing 5.5% PEG 35000 and 49.5% PEG 1450 had an acceptable viscosity (705 cP) at 75° C./50 rpm, the stability tests revealed that this formulation was a very viscous liquid at 40° C./75% RH, and thus was not stable for storage. Because the formulations containing 11% PEG 35000 (batch number 100) and 5.5% PEG 35000 (batch number 101) were not sufficiently stable for storage, stability of batch number 103 containing 7.7% PEG 35000 was not determined.


Formulations containing PEG 35000 and PEG 3350 were also evaluated. As shown in Table 6 below, the formulation containing 6.97% PEG 35000 and 62.7% PEG 3350 (batch number 104) and the formulation containing 7.7% PEG 35000 and 69.3% PEG 3350 (batch number 105) met all of the criteria for particle size after grinding, viscosity, and stability.









TABLE 6







Particle size, Viscosity, and Stability for Oxycodone HCl Formulations Containing PEG 35000.












Excipients
Grinding/


























Capsule
Particle

Stability



%
%
%

%

Target
Size

at



















PEG
PEG
PEG
Peg
Grey
%
Weight
% ≧500
% <500
Viscosity
40° C./


Batch
35000
3350
1450
Ratio
Dye
API
(mg)
μm***
μm
(cP)
75% RH





















97
27.5
0
27.4
50:50
14
30
100
83.0
17.0
NA
Softened













Wax,













non-













liquid


98
22

33
40:60



91.4
8.6
NA
Softened













Wax,













non-













liquid


99
16.5

38.5
30:70



90.1
9.9
NA
Semi-













solid


100
11

44
20:80



95.7
4.3
1288
Very













viscous













liquid


101
5.5

49.5
10:90



99.6
0.4
705
Very













viscous













liquid


103
7.7

69.3
10:90
7
15
200
NA
NA
298
NA


102
5.5
49.5
0
10:90
14
30
100
78.8
21.2
1045
Softened













Wax,













non-













liquid


104
6.97
62.7

10:90
9.33
20
150
79.9
20.1
745
Softened













Wax,













non-













liquid


105
7.7
69.3

10:90
7
15
200
77.5
22.5
620
Softened













Wax,













non-













liquid


106
15.4
61.6

20:80
7
15
200
85.1
14.9
1375
NA









Example 3
Evaluation of Dyes

Numerous dyes were evaluated for their potential to deter intravenous abuse. Varying concentrations of FD&C Blue #2, green (FD&C Blue #2 and FD&C Yellow #5), FD&C Yellow #5, FD&C Red #40, and grey dye (FD&C Blue#1, FD&C Yellow #6, FD)&C Red #40) were evaluated by dissolving them in a 95% ethanol 5% purified water (190 proof) solution and passing the solution through a syringe filter. After syringe filtering the dye solutions were visually evaluated for color intensity and rated on a scale of 0 to 5, with 0 indicating no color and 5 indicating dark, significant color. As shown in the Table 7 below, the blue and green dyes exhibited the highest color intensity at low concentrations, e.g. 0.25% w/w. Solutions of grey dye before and after filtering are shown in FIGS. 2A and 2B, respectively. The grey dye was particularly striking and less appealing. An acceptable color scale designation after extraction of the dye is ≧4 on a scale of 1 to 5, with 5 being the highest level of color.









TABLE 7







Evaluation of Various Dyes at Varying Concentrations in


190 Proof Alcohol











Batch
Dye Color
Dye (% w/w)
Dye (mg)
Color Number*














66
Blue
0.25
1.75
4


67
Blue
0.50
3.50
5


68
Blue
0.75
5.25
5


69
Blue
1.00
7.00
5


70
Green
0.25
1.75
4


71
Green
0.50
3.50
4


72
Green
0.75
5.25
4


73
Green
1.00
7.00
4


74
Yellow
0.25
1.75
3


75
Yellow
0.50
3.50
4


76
Yellow
0.75
5.25
5


77
Yellow
1.00
7.00
5


78
Red
0.11
0.75
2


79
Red
0.21
1.50
3


80
Red
0.43
3.00
4


81
Red
0.63
4.44
5


82
Grey
0.25
1.75
2


83
Grey
0.50
3.50
2


84
Grey
0.75
5.25
4


85
Grey
1.00
7.00
4


86
Grey
2.00
14.00
5









In one embodiment, the dye can be grey. Grey can be chosen because it is darker than the others and can be effective at a lower relative concentration. Grey dye can allow for the most visually deterring form with the least amount of dye present in the formulation.


Example 4
Immediate Release ADF Oxycodone HCl Liquid Fill Capsules

Abusers of opioid products often adulterate the product to promote more rapid release of the active ingredient. The products can be chewed and swallowed, crushed and inhaled, or extracted in water or alcohol (either crushed or intact) to produce a solution that can be used for intravenous administration or dried for insufflation of a purified product. Adulteration of the products can enable a more rapid delivery of active than can be achieved by ingestion of the intact product. This rapid onset, high exposure is associated with euphoria, drug liking, and greater abuse potential.


Current abuse-deterrent formulations have limitations. Insufflation is a common route of abuse for oxycodone HCl products. To be attractive for insufflation, crushing a product should yield particles of less than 500 μm to allow uptake of the active substance though the nasal mucosa. Therefore, abuse deterrent formulations can be made to discourage crushing or breaking of tablets to yield particles less than 500 μm. Test methods using flat platens to crush the product as a criterion for abuse deterrence is not meaningful. All C-II narcotic drug products tested can be cut with an edged surface (e.g., scissors or a razor blade) and therefore can potentially be abused, with forces that are substantially lower than what has been reported using the breaking strength test or equivalent (e.g., >500 N). Flattening the tablets using forces greater than 500 N (with traditional “tablet breaking force” definitions) does not address abuse deterrence potential in the tested C-II narcotic drug products.


Grinding can be a better evaluation of the relative resistance of marketed products to abuse. The formulation of the present disclosure compares favorably against Roxicodone® with respect to a decrease in the percentage of particles produced after grinding that are smaller than 500 μm. Statistically different results emerge between the formulation of the present disclosure and Roxicodone® in the degree of resistance to grinding, with the formulation of the present disclosure yielding less than 50% of particles smaller than 500 μm, compared with approximately 77% of particles less than 500 μm for Roxicodone®. Better resistance to grinding can be due to differences in the manufacturing processes and/or the excipients employed for the two products.


The formulation of the present disclosure can be resistant to abuse by nasal insufflation or extraction due to, in part, the waxy nature of the formulation contents and the solubility of the excipients. The excipients can be both water and alcohol soluble to create a formulation that makes it time consuming and costly to extract oxycodone HCl from the formulation contents without also extracting the excipients. A high molecular weight PEG can be included because of its solubility properties (e.g., soluble in both alcohol and water) and its resistance to grinding to particle sizes of less than 500 μm. High-molecular weight PEGs are less viscous at melt temperatures than long chain PEO molecules and are soluble in both water and alcohol.


Dyes can also be used and chosen to be soluble in both water and alcohol to produce a dark colored solution upon extraction and filtering as a visual deterrent to abuse. The formulation can include the following components listed in the Table 8 below, including a number of different dyes. Table 8 below lists the components along with their solubility information taken from the various literature sources and tested experimentally (e.g., 200 proof ethanol and filtered through a 0.45 micrometer PTFE filter). The extraction of the active to a pure form can be very difficult using water or alcohol.









TABLE 8







Solubility of the Components of the Present Disclosure Formulation












Alcohol
Alcohol



Water
Solubility
Solubility


Components
Solubility
(Literature)
(Tested)





Oxycodone HCl
Yes
Yes
Yes


Hydrocodone Bitartrate
Yes
Slightly
N/A


Polyethylene Glycol USP NF
Yes
Yes
N/A


Anhydrous Citric Acid
Yes
Yes
N/A


FD&C Blue #1
Yes
Yes
Yes


FD&C Yellow #6
Yes
Yes
Yes


FD&C Red #40
Yes
Yes
Yes









A conventional tablet or powder-filled capsule can be easily crushed to create a fine powder. The waxy material contained in the formulations of the present disclosure can make it difficult to manipulate into particles small enough to be easily absorbed by the nasal mucosa. The waxy material may also congeal once introduced to the semi-aqueous environment of the nasal passages, which can make it difficult to introduce the oxycodone HCl or hydrocodone bitartrate to the bloodstream via the nasal passages.


The formulations of the present disclosure can contain one or more of the following barriers to abuse. Insufflation—The formulation can be formulated to resist grinding to particle sizes of less than about 500 m. Extraction and Purification—The formulation can be formulated with water-and alcohol-soluble dyes to create a dark colored solution upon extraction that can be visually unappealing to intravenous drug users. The water-and alcohol-soluble excipients can present obstacles to purification of the active. In some formulations, if the solvent is flashed off or otherwise evaporated, the excipients can return to the same waxy, dark-colored form as before being introduced to the solvent. Vaporization—The formulation can contain an active, such as oxycodone HCl, which can degrade at temperatures close to where vaporization occurs. Chewing—Because the formulation is an immediate release formulation, it is not expected that crushing or cutting the dosage form will result in an especially rapid release of the drug to produce a “euphoric high.”


Table 9 below lists exemplary formulations for the oxycodone HCI abuse deterrent formulation capsules.









TABLE 9







Quantitative Composition of Oxycodone HCl ADF Capsules










Ingredients
Capsule Quantity (mg)







Oxycodone HCl USP API
 5-30



Polyethylene Glycol 3350
100-150



Polyethylene Glycol 35,000
 5-25



Anhydrous Citric Acid
1-2



Dye Blend




FD&C Red #40 (DB-175000)
0.5-1.0



FD&C Yellow #6 (DB-175000)
0.3-0.6



FD&C Blue #1 (DB-175000)
0.1-0.3



Polyethylene Glycol 3350 (DB-175000)
10-15



Gelatin (Capsule)




Total Fill Weight per Capsule
100-200










Formulations of the present disclosure were manufactured by the following exemplary process. The components of the hot-melt suspension, consisting of Polyethylene Glycol 3350, Polyethylene Glycol 35000, Dye Blend, Grey Powder, Citric Acid and Oxycodone HCl were dispensed according to theoretical batch quantities based on formulation weight percents.


Polyethylene Glycol 3350, Polyethylene Glycol 35000, Dye Blend, Grey Powder, Oxycodone HCl and Citric Acid were added to an Olsa 150 Liter Kettle and heated to a temperature of 70±20° C. Utilizing the homogenizer mixer, external anchor blades and internal mixing blades, the melt was then mixed until uniform


Prior to transferring the hot-melt suspension from the kettle to the Shionogi F40 capsule filling machine hopper, a transfer pump and three heat traced hoses were set up and the melt/suspension was recirculated. Mixing and recirculating continued until capsule filling was completed.


The Shionogi F40 capsule filling machine target fill weight was set with an Action Limit of ±3.5% and a Control Limit of ±5.0% plus the average empty capsule weight.


In-process capsule samples were taken at the beginning, end, and every 30 minutes (for the average capsule weight of 15 filled capsules). Filled capsules were placed onto stainless steel cooling trays and allowed to cure. Following curing, 100% capsule weight inspection was performed using a Shionogi capsule weight inspection machine An exemplary manufacturing process is shown in FIG. 3.


The formulations of the present disclosure are stable upon storage at 25, 30, 35, 40 or 45° C., and at 60%, 65%, 70% or 75% relative humidity, e.g., 30° C./65% RH or 40° C./75% RH. The formulation of the present disclosure can be stable under any of these conditions for up to 1, 2, 3, 4, 5, 6, 9, 12, 16, 18, 24, or 36 months.


Example 5
Abuse Deterrent Properties of Immediate Release Liquid Fill Capsule PEG Formulations

In one embodiment, there are at least three determining factors which deem an immediate release drug product “abuse deterrent,” namely resistance to grinding, purity upon extraction, and visual evaluation following extraction. Cutting the dosage form can be performed in order to increase the surface area of the product prior to ingesting it in an effort to increase the rate of dissolution into the digestive tract. Cutting can also be used to increase the efficiency of grinding or extraction. Cutting alone, however, is not sufficient to render a formulation abusable. Grinding the dosage form can be performed in order to decrease the particle size of the product more efficiently than cutting in an effort to insufflate (snort) for immediate release into the blood vessels of the nasal passages. A readily available tool used for grinding is a commercially available coffee grinder. In one embodiment, a drug product is considered abuse deterrent if the % material in the pan (≦500 μm) is ≦50%. A dosage form which, when ground, produces ≦50% of the material on a per-dosage form basis available for nasal insufflation (≦500 μm) is considered abuse deterrent. The purpose of this study was to determine the grinding potential of different dosage forms of oxycodone HCl. Texture analysis is the mechanical testing of pharmaceutical products in order to measure their physical properties. The Retsch Knife Mill GRINDOMIX GM200 (TE96) was utilized to mimic a commercially available coffee grinder (Mr. Coffee) in order to grind the drug products into a particle size that is suitable for intranasal abuse (insufflation). Particle size analysis was conducted utilizing an ATM L3P Sonic Sifter (TE147), utilizing a 500 micrometer (μm) particle size sieve (35 mesh). For the purposes of this study, any particle less than 500 μm in diameter is considered suitable for intranasal abuse. It is generally accepted that any particle greater than 500 μm in diameter cannot be sufficiently absorbed by the blood vessels in the nasal passages.


The Retsch Knife Mill GRINDOMIX GM200 utilizes a circular blade attachment to mimic commercially available coffee grinders. The GM200 has a top speed of 10,000 revolutions per minute (rpm), while commercially available coffee grinders have a top speed of approximately 20,000 rpm (an approximate two-fold increase in speed when comparing the GM200 to a Mr. Coffee grinder). However, the approximate two-fold increase in blade diameter (118 mm vs. 60 mm, when comparing the GM200 to a Mr. Coffee grinder, respectively) compensates for the approximate twofold decrease in top speed via the inversely proportional relationship of the two variables. Further, the torque provided by the GM200 is significantly higher than the torque provided by a Mr. Coffee grinder (0.860 Nm (Newton meters) of the GM200 vs. 0.062 Nm of the Mr. Coffee grinder, respectively), which additionally illustrates the ability (or lack thereof) of the Mr. Coffee grinder to modify the drug products into a particle size suitable for intranasal abuse. The study evaluated the difference in particle sizes of several different formulations of oxycodone HCl following modification (grinding) by the GM200.


Experimental: The samples tested are formulated according to Table 9. The following test equipment was used: Retsch Knife Mill GRINDOMIX GM200 (TE96), ATM L3P Sonic Sifter (TE47), and a 500 μm sieve (35 mesh). The following testing conditions were used: Analysis speed: 10,000 rpm; Analysis time: 30 seconds; Sieve Size: 500 μm (35 mesh); Analysis time: 1 minutes (no pulse). Each sample was prepared in triplicate (N=3).


The composite sample was transferred to a tared weigh boat and the weight of the sample was recorded. The following equation was used to calculate the % sample loss:







Sample





Loss






(
%
)


=

100
-

(



Analyzed





Sample






(
mg
)



Sample





Weight






(
mg
)



×
100

)






The weight of the 35 mesh sieve and sample pan was recorded. The testing apparatus was assembled with the 35 mesh sieve above the sample pan. The composite sample was transferred to the testing apparatus and analyzed utilizing the following parameters: 1 minute analysis time and no pulse. The analyzed 35 mesh sieve and sample pan were weighed. The % material remaining on the 35 mesh sieve (≧500 μm) and in the sample pan (≦500 μm) was calculated using the following equation:







Percent





on





Sieve






(
%
)


=



Weight





of





Sample





on





Sieve






(
mg
)



Total





Weight





of





Sample





on





Sieve






(
mg
)



×
100





Table 10 below shows the particle size after grinding for the oxycodone HCl formulations tested. During testing it was observed by visual observation that the capsule portion of the dosage form of all evaluated batches was not being significantly modified by TE96, and that the majority of the capsule portion remained in the 35 mesh sieve (≧500 μm). The grinding/particle size analysis for this protocol is based on weight differences, which, when the capsule portion is taken into account, can skew the results towards a higher proportion of particles ≧500 μm.


In order to confirm the particle size of capsules modified by TE96, three empty size 3 capsules (N=1) were ground and analyzed. Table 11 shows that for size 3 capsules, 99% of the particles by weight were ≧500 μm. Additional calculations were made which compensated for the percentage of capsules ≧ or <500 μm. These calculations removed the average capsule weight from the analyzed sample by subtracting it from the weight ≧500 μm and the weight <500 μm. The results adjusted for capsule weight are shown in Table 12.









TABLE 10







Particle size after grinding of oxycodone HCl


capsules before adjusting for capsule weight.


% RSD is percent relative standard deviation















Present
Present
Present





Disclosure
Disclosure
Disclosure



Location
Replicate
5 mg
15 mg
30 mg

















35 Mesh
1
73.2
73.8
79.0



(≧500
2
75.9
82.2
79.2



μm) %
3
72.7
78.5
77.7




Minimum
72.7
73.8
77.7




Maximum
75.9
82.2
79.2




Average
74.0
78.1
78.7




% RSD
2.3
5.4
1.0



Pan
1
26.8
26.2
21.0



(<500
2
24.1
17.8
20.8



μm) %
3
27.3
21.5
22.3




Minimum
24.1
17.8
20.8




Maximum
27.3
26.2
22.3




Average
26.0
21.9
21.3




% RSD
6.6
19.3
3.8

















TABLE 11







Particle size of empty size 3 capsules after grinding




















Tare

After

35




Initial
After
% Loss
35
Tare
35
After
Mesh
Pan



Wt
Grinding
In
Mesh
Pan
Mesh
Pan
(≧500
(<500


Product
(mg)
(mg)
Grinding
(g)
(g)
(g)
(g)
μm) %
μm) %



















Size 3
143.8
144.5
−0.5
40.8367
4.4111
40.9724
4.4124
99.1
0.9


Capsules









As shown in Table 12, after adjusting for the capsule portion, the average percentage of particles ≧500 μm after grinding for the oxycodone HCl capsules ranged from 62.3% to 68.2%. For comparison, approximately 20% of particles by weight of an Immediate Release (IR) Roxicodone® formulation were ≧500 μm after the same grinding procedure.









TABLE 12







Particle size after grinding of oxycodone HCl


dosage forms, adjusted for capsule weight.


% RSD is percent relative standard deviation.















Present
Present
Present





Disclosure
Disclosure
Disclosure



Location
Replicate
5 mg
15 mg
30 mg

















35 Mesh
1
60.9
60.8
67.4



(≧500
2
63.6
72.8
69.0



μm) %
3
56.3
68.0
66.9




Minimum
56.3
60.8
66.9




Maximum
63.6
72.8
69.0




Average
62.3
66.8
68.2




% RSD
6.1
9.0
1.7



Pan
1
39.1
39.2
32.6



(<500
2
36.4
27.2
31.0



μm) %
3
43.7
32.0
33.1




Minimum
36.4
27.2
31.0




Maximum
43.7
39.2
33.1




Average
39.7
32.8
32.2




% RSD
9.3
18.4
3.5










Table 13 summarizes the grinding results and statistical analysis of the % material ≦500 μm for the Present Disclosure 15 mg and Roxicodone® 15 mg tablets (Mallinckrodt Pharmaceuticals, Inc.).









TABLE 13







Particle Size Analysis of 15 mg Dosages of Roxicodone ®


and the Present Disclosure


Grinding Result














%




Statis-



Particles
Aver-
%
F-

tically


Product
≦500 μm
age
RSD
test
t-test
Different?





Roxicodone ®
76
76
1.9
0.672
4.85E−06
Yes


15 mg-1








Roxicodone ®
75







15 mg-2








Roxicodone ®
78







15 mg-3








Present
43
43
2.4





Disclosure








15 mg-1








Present
42







Disclosure








15 mg-2








Present
44







Disclosure








15 mg-3









Another method of rending a drug product abusable is via extraction of the active substance from the dosage form to produce a pure residue. This method can be performed, and is often performed, using a high proof alcohol or an aqueous media. The formulation of the present disclosure can be readily soluble in both aqueous and alcohol environments when the contents are removed from the capsule. Therefore, aqueous and alcohol extraction techniques were evaluated. Solutions were analyzed qualitatively for solution color following filtration, as well as quantitatively for % label claim (LC) (with regards to oxycodone HCl) of solution following filtration. Additionally, evaporated residual samples were analyzed qualitatively for residue color following evaporation, as well as quantitatively for purity determination following the % LC calculations. The quantitative results of the analysis determine the % purity (with regards to oxycodone HC) of the extracted sample solution described above. A drug product can be considered abuse deterrent if the % residue purity is ≦50%. In other embodiments, less than or equal to 40%, 45%, 55%, 60%, 65%, 70% or 75%. Residue purity levels (with regards to the API)≦50% can infer that the excipient load is greater than the API level contained in the residue. In one embodiment, this can be considered abuse deterrent with regards to potential intravenous abuse of a purified residue. Using the data analysis software functionality of Microsoft Excel and a 95% significance interval (p-value=0.05), the F-test and t-tests was analyzed in order to determine if the drug products provide statistically different % purity values.


Tables 14 and 15 show the formulation of the present disclosure results in 9% and 9% purity with regards to oxycodone HCl, in alcohol and aqueous environments, respectively. This is in comparison to Roxicodone® 15 mg, which has a purity of 68% and 19% purity in alcohol and aqueous environments, respectively. This data proves the formulation of the present disclosure is statistically different than Roxicodone® in both alcohol and aqueous extracts.









TABLE 14







% Purity Results—Alcohol



















Statis-




Aver-
%
F-

tically


Product
% Purity
age
RSD
test
t-test
Different?
















Roxicodone ®
66
68
2.5
0.208
5.77E−07
Yes


15 mg-1








Roxicodone ®
69







15 mg-2








Roxicodone ®
68







15 mg-3








Present
10
9
6.4





Disclosure








15 mg-1








Present
8







Disclosure








15 mg-2








Present
9







Disclosure








15 mg-3
















TABLE 15







% Purity Results—Aqueous



















Statis-




Aver-
%
F-

tically


Product
% Purity
age
RSD
test
t-test
Different?
















Roxicodone ®
20
19
2.6
0.823
1.02E−05
Yes


15 mg-1








Roxicodone ®
19







15 mg-2








Roxicodone ®
19







15 mg-3








Present
10
9
4.6





Disclosure








15 mg-1








Present
9







Disclosure








15 mg-2








Present
9







Disclosure








15 mg-3









Color is one identifying characteristic of commercial drug products. Color can be applied to the dosage form in two ways: dye or coating. High potency alcohol (i.e., ≧190 proof (95%)) is one extraction solvent that can be used by abusers for APIs which are insoluble in water or in order to separate the API from other water soluble excipients. Dyes or coatings can potentially be used to alter the physical appearance of the extracted solution of drug product (i.e., turn the resulting solution a noticeable color).


Accordingly, the inclusion of one or more dyes in a drug formulation is one method to render a formulation abuse deterrent. Significant discoloration of an extraction product from a formulation subject to abuse can discourage a potential abuser from using (e.g., injecting or ingesting) the extraction product.


A study was conducted to investigate the effect of dyes in the formulations of the present disclosure. Extraction products from whole formulations were visually inspected to determine abuse deterrence following alcohol extraction. Capsules were added to a flask containing 190 proof ethanol and shaken at 250 rpm for 3 hours. After 3 hours all capsule contents were fully dissolved. Solutions were filtered with a syringe filter and then visually analyzed for color intensity. The samples tested were the immediate release oxycodone HCl capsules according to Table 9 above.


The unfiltered and filtered solutions are shown in FIGS. 4 and 5, respectively. As shown in Table 16 below, all of the filtered solutions had a color value of 5, indicating that all seven evaluated batches produced a filtered solution which was significantly dark in color. This significant dark color provides potential abuse deterrence to CII narcotic drug products.









TABLE 16







Color Scale Designation—Post-Syringe Filter Analysis for


Oxycodone HCl Formulations of the Present Disclosure










Active thgredient(s)
Color Value







 5 mg oxycodone HCl
5



15 mg oxycodone HCl
5



30 mg oxycodone HCl
5










Additionally, the color of filtered solutions and resulting evaporated residues of alcoholic and aqueous extracts of the formulations of the present disclosure and Roxicodone® were compared. Table 17 below shows both of these dosage forms, with the formulation of the present disclosure providing the most visual deterrence for both the filtered solution and evaporated residue in both media.













TABLE 17











Color Determination














Filtered
Evaporated



Product
Solution
Solution
Residue







Roxicodone ® 15 mg
Alcohol
1
3




Aq.
0
3



Present Disclosure 15 mg
Alcohol
5
5




Aq.
5
5










While this disclosure has been particularly shown and described with reference to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims
  • 1. An immediate release, abuse deterrent capsule comprising: (a) an active substance susceptible to abuse;(b) a first polyethylene glycol (PEG) having an average molecular weight of 35,000 Daltons; and(c) a second PEG having an average molecular weight between about 3350 Daltons, wherein the ratio of the first PEG to the second PEG is less than about 1:4 w/w.
  • 2. The capsule of claim 1, wherein the first PEG and the second PEG together are at least about 60 wt % of the dosage form.
  • 3. The capsule of claim 1, wherein at least 80% of the contents are soluble both water and alcohol.
  • 4. The capsule of claim 1, wherein the active substance is hydrocodone bitartrate.
  • 5. The capsule of claim 1, wherein the active substance is oxycodone HCl.
  • 6. The capsule of claim 1, further comprising a grey dye comprising FD&C Blue #1, FD&C Yellow #6, and FD&C Red #40.
  • 7. The capsule of claim 6, wherein the dye provides a visual deterrent to abuse.
  • 8. The capsule of claim 1, wherein the ratio of the first PEG to the second PEG is between about 1:7 w/w and about 1:11 w/w.
  • 9. The capsule of claim 1, wherein the capsule comprises at least about 2.5 wt % of the active substance.
  • 10. The capsule of claim 1, wherein the capsule is prepared by filling a capsule body with a heated homogenized suspension comprising the active substance, the first PEG and the second PEG.
  • 11. A process for the production of an immediate release, abuse deterrent capsule comprising at least one active substance susceptible to abuse comprising: (a) preparing a homogenized suspension of: (i) the at least one active substance susceptible to abuse;(ii) a first PEG having an average molecular weight of 35,000 Daltons; and(iii) a second PEG having an average molecular weight of 3350 Daltons; and(b) filling the homogenized suspension into a capsule body to produce the capsule, wherein the ratio of the first PEG to the second PEG is less than about 1:4 w/w.
  • 12. The process of claim 11, wherein the first PEG and the second PEG together are at least about 60 wt % of the capsule.
  • 13. The process of claim 11, wherein the active substance is hydrocodone bitartrate.
  • 14. The process of claim 11, wherein the active substance is oxycodone HCl.
  • 15. The process of claim 11, wherein the capsule is formed by joining a capsule body with a capsule cap.
  • 16. A method of treating pain comprising administering to a subject in need thereof a therapeutically effective amount of the capsule of claim 1.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/025,878 filed Jul. 17, 2014, the disclosure of which is incorporated herein by reference in their entirety.

US Referenced Citations (450)
Number Name Date Kind
3439069 Cherkas et al. Apr 1969 A
4450877 Walker et al. May 1984 A
5141961 Coapman Aug 1992 A
5202128 Morella et al. Apr 1993 A
5266331 Oshlack et al. Nov 1993 A
5431916 White Jul 1995 A
5458879 Singh et al. Oct 1995 A
5614218 Olsson et al. Mar 1997 A
5616621 Popli et al. Apr 1997 A
5827852 Russell et al. Oct 1998 A
5840337 Cody et al. Nov 1998 A
5840731 Mayer et al. Nov 1998 A
5866164 Kuczynski et al. Feb 1999 A
5914129 Mauskop Jun 1999 A
6024980 Hoy Feb 2000 A
6068855 Leslie et al. May 2000 A
6102254 Ross Aug 2000 A
6159501 Skinhoj Dec 2000 A
6160020 Ohannesian et al. Dec 2000 A
6190591 van Lengerich Feb 2001 B1
6207674 Smith Mar 2001 B1
6245357 Edgren et al. Jun 2001 B1
6251430 Zhang et al. Jun 2001 B1
6277384 Kaiko et al. Aug 2001 B1
6309669 Setterstrom et al. Oct 2001 B1
6432450 Gergely et al. Aug 2002 B1
6488963 McGinity et al. Dec 2002 B1
6500459 Chhabra et al. Dec 2002 B1
6572891 Ugarkovic Jun 2003 B1
6627635 Palermo et al. Sep 2003 B2
6706281 Oshlack et al. Mar 2004 B2
6713470 Jackson Mar 2004 B2
6740333 Beckett et al. May 2004 B2
6753009 Luber et al. Jun 2004 B2
6800668 Odidi et al. Oct 2004 B1
6869618 Kiel et al. Mar 2005 B2
6905709 Oshlack et al. Jun 2005 B2
6923988 Patel et al. Aug 2005 B2
7141250 Oshlack et al. Nov 2006 B2
7201920 Kumar et al. Apr 2007 B2
7214385 Gruber May 2007 B2
7316821 Oshlack et al. Jan 2008 B2
7384653 Wright, IV et al. Jun 2008 B2
7413750 Kolter et al. Aug 2008 B2
7514100 Oshlack et al. Apr 2009 B2
7544676 Dolle et al. Jun 2009 B2
7655256 Hughes Feb 2010 B2
7666337 Yang et al. Feb 2010 B2
7670612 Miller Mar 2010 B2
7670627 Shefer et al. Mar 2010 B2
7718194 Chenevier et al. May 2010 B2
7744916 Pauletti et al. Jun 2010 B2
7754240 Staniforth et al. Jul 2010 B2
7780987 Zhou et al. Aug 2010 B2
7790215 Sackler et al. Sep 2010 B2
7842307 Oshlack et al. Nov 2010 B2
7846460 Chenevier et al. Dec 2010 B2
7846476 Oshlack et al. Dec 2010 B2
7910128 Chang et al. Mar 2011 B2
7943173 Breder et al. May 2011 B2
7968119 Farrell Jun 2011 B2
8029822 Faour et al. Oct 2011 B2
8075872 Arkenau-Maric et al. Dec 2011 B2
8114383 Bartholomaus et al. Feb 2012 B2
8124126 Bosse et al. Feb 2012 B2
8133507 Yum et al. Mar 2012 B2
8138169 Oronsky et al. Mar 2012 B2
8143267 Burch et al. Mar 2012 B2
8188108 Mayo-Alvarez et al. May 2012 B2
8202542 Mehta et al. Jun 2012 B1
8216610 Roberts et al. Jul 2012 B2
8263125 Vaya et al. Sep 2012 B2
8313757 van Lengerich Nov 2012 B2
8318105 Selinfreund et al. Nov 2012 B2
8318641 Selinfreund et al. Nov 2012 B2
8333989 Sukuru Dec 2012 B2
8337888 Wright et al. Dec 2012 B2
8362029 Evenstad et al. Jan 2013 B2
8377453 Han et al. Feb 2013 B2
8383152 Jans et al. Feb 2013 B2
8394813 Mickle et al. Mar 2013 B2
8415401 Yum et al. Apr 2013 B2
8420114 Zanella et al. Apr 2013 B2
8426411 Wishart et al. Apr 2013 B2
8445023 Guimberteau et al. May 2013 B2
8465776 Hoarau Jun 2013 B2
8481560 Stinchcomb et al. Jul 2013 B2
8486448 Rahmouni et al. Jul 2013 B2
8486449 Rahmouni et al. Jul 2013 B2
8497303 Wurn et al. Jul 2013 B2
8501160 Cailly-Dufestel et al. Aug 2013 B2
8518438 Rashid et al. Aug 2013 B2
8524267 Zanella et al. Sep 2013 B2
8563038 Andersen et al. Oct 2013 B2
8575196 Riggs-Sauthier et al. Nov 2013 B2
8591947 Vergez et al. Nov 2013 B2
8597681 Park et al. Dec 2013 B2
8603514 Yang et al. Dec 2013 B2
8603525 Oury et al. Dec 2013 B2
8609143 Fischer et al. Dec 2013 B2
8617605 Fischer et al. Dec 2013 B2
8623401 Modi Jan 2014 B2
8623412 Farid et al. Jan 2014 B2
8652511 Cottrell et al. Feb 2014 B2
8653066 Bosse Feb 2014 B2
8658631 Devarakonda et al. Feb 2014 B1
8685381 Schlessinger et al. Apr 2014 B2
8709479 Oury et al. Apr 2014 B2
8722086 Arkenau-Mari et al. May 2014 B2
20010031278 Oshlack et al. Oct 2001 A1
20010044472 Upadhyay et al. Nov 2001 A1
20010046971 Hammerly Nov 2001 A1
20020055512 Marin et al. May 2002 A1
20020068718 Pierce Jun 2002 A1
20020099013 Piccariello et al. Jul 2002 A1
20020164373 Maloney Nov 2002 A1
20030049318 Davis et al. Mar 2003 A1
20030068375 Wright et al. Apr 2003 A1
20030091635 Baichwal et al. May 2003 A1
20030092724 Kao et al. May 2003 A1
20030117622 Sevick-Muraca et al. Jun 2003 A1
20030125347 Anderson et al. Jul 2003 A1
20030180362 Park et al. Sep 2003 A1
20030185761 Dugger Oct 2003 A1
20030191147 Sherman et al. Oct 2003 A1
20030199439 Simon Oct 2003 A1
20030199496 Simon Oct 2003 A1
20030203027 Verreck et al. Oct 2003 A1
20030206898 Fischkoff et al. Nov 2003 A1
20030224051 Fink et al. Dec 2003 A1
20030235618 Moros et al. Dec 2003 A1
20040009172 Fischkoff et al. Jan 2004 A1
20040010000 Ayer et al. Jan 2004 A1
20040022787 Cohen et al. Feb 2004 A1
20040029864 MacMillan Feb 2004 A1
20040043071 Pauletti et al. Mar 2004 A1
20040062778 Shefer et al. Apr 2004 A1
20040110781 Harmon et al. Jun 2004 A1
20040122104 Hirsh et al. Jun 2004 A1
20040156872 Bosch et al. Aug 2004 A1
20040157928 Kim et al. Aug 2004 A1
20040224020 Schoenhard Nov 2004 A1
20040228802 Chang et al. Nov 2004 A1
20040259948 Tontonoz et al. Dec 2004 A1
20040265378 Peng et al. Dec 2004 A1
20050004098 Britten et al. Jan 2005 A1
20050013857 Fu et al. Jan 2005 A1
20050020613 Boehm et al. Jan 2005 A1
20050026842 Simon Feb 2005 A1
20050059023 Cantor Mar 2005 A1
20050106249 Hwang et al. May 2005 A1
20050143471 Gao et al. Jun 2005 A1
20050152905 Omoigui Jul 2005 A1
20050169990 Kao et al. Aug 2005 A1
20050222136 Buschmann et al. Oct 2005 A1
20050226929 Xie et al. Oct 2005 A1
20050233459 Melker et al. Oct 2005 A1
20050245483 Brogmann et al. Nov 2005 A1
20050265955 Raman et al. Dec 2005 A1
20050266032 Srinivasan et al. Dec 2005 A1
20050266072 Oshlack et al. Dec 2005 A1
20060008527 Lagoviyer et al. Jan 2006 A1
20060009478 Friedmann et al. Jan 2006 A1
20060024365 Vaya et al. Feb 2006 A1
20060024368 Fassihi et al. Feb 2006 A1
20060039865 Preston et al. Feb 2006 A1
20060052278 Powell Mar 2006 A1
20060062734 Melker et al. Mar 2006 A1
20060067971 Story et al. Mar 2006 A1
20060073182 Wong et al. Apr 2006 A1
20060074422 Story et al. Apr 2006 A1
20060079557 Dolle et al. Apr 2006 A1
20060093663 Suzuki May 2006 A1
20060099254 Desai et al. May 2006 A1
20060110327 Emigh et al. May 2006 A1
20060111307 Robbins May 2006 A1
20060115527 Hassan et al. Jun 2006 A1
20060153915 Park et al. Jul 2006 A1
20060165790 Walden et al. Jul 2006 A1
20060177380 Emigh et al. Aug 2006 A1
20060177381 Brooks-Korn Aug 2006 A1
20060205752 Whitehead Sep 2006 A1
20060210604 Dadey et al. Sep 2006 A1
20060210631 Patel et al. Sep 2006 A1
20060240105 Devane et al. Oct 2006 A1
20060246134 Venkatesh Nov 2006 A1
20060263429 Feng Nov 2006 A1
20060292214 Jenkins et al. Dec 2006 A1
20070003617 Fischer et al. Jan 2007 A1
20070003622 Srinivasan et al. Jan 2007 A1
20070009444 Yamaguchi Jan 2007 A1
20070020339 Bear Jan 2007 A1
20070027203 Chen et al. Feb 2007 A1
20070042969 Rauschkolb-Loffler et al. Feb 2007 A1
20070048228 Arkenau-Maric et al. Mar 2007 A1
20070048377 Rajabi-Siahboomi et al. Mar 2007 A1
20070072982 Choi et al. Mar 2007 A1
20070087977 Robbins Apr 2007 A1
20070104788 Mulligan May 2007 A1
20070134493 Meghpara Jun 2007 A1
20070140983 Hall et al. Jun 2007 A1
20070148239 Hall et al. Jun 2007 A1
20070167438 Rosenzweig-Lipson Jul 2007 A1
20070190142 Breitenbach et al. Aug 2007 A1
20070196491 Venkatesh Aug 2007 A1
20070197661 Bubnis et al. Aug 2007 A1
20070207200 Plachetka et al. Sep 2007 A1
20070207222 Yu et al. Sep 2007 A1
20070212417 Cherukuri Sep 2007 A1
20070213717 Trieu et al. Sep 2007 A1
20070213718 Trieu Sep 2007 A1
20070213822 Trieu Sep 2007 A1
20070213823 Trieu Sep 2007 A1
20070213824 Trieu Sep 2007 A1
20070215511 Mehta et al. Sep 2007 A1
20070231268 Emigh et al. Oct 2007 A1
20070232529 Mickle et al. Oct 2007 A1
20070244093 Boehm et al. Oct 2007 A1
20070249566 Martin et al. Oct 2007 A1
20070254027 Martin et al. Nov 2007 A1
20070281016 Kao et al. Dec 2007 A1
20070281017 Kao et al. Dec 2007 A1
20070281018 Qiu et al. Dec 2007 A1
20070292461 Tamarkin et al. Dec 2007 A1
20070292508 Szamosi et al. Dec 2007 A1
20070292510 Huang Dec 2007 A1
20070298103 Hayes Dec 2007 A1
20080014228 Darmuzey et al. Jan 2008 A1
20080014274 Bubnis et al. Jan 2008 A1
20080020032 Crowley et al. Jan 2008 A1
20080020039 Parikh et al. Jan 2008 A1
20080026040 Farr et al. Jan 2008 A1
20080026062 Farr et al. Jan 2008 A1
20080031901 Qiu et al. Feb 2008 A1
20080057122 Toney-Parker et al. Mar 2008 A1
20080063725 Guimberteau et al. Mar 2008 A1
20080069871 Vaughn et al. Mar 2008 A1
20080069878 Venkatesh et al. Mar 2008 A1
20080069889 Cherukuri Mar 2008 A1
20080081071 Sanghvi et al. Apr 2008 A1
20080085304 Baichwal et al. Apr 2008 A1
20080085312 Wilson et al. Apr 2008 A1
20080102113 Rosenberg May 2008 A1
20080102123 Schachter et al. May 2008 A1
20080103206 Swann et al. May 2008 A1
20080132751 Keller et al. Jun 2008 A1
20080152595 Emigh et al. Jun 2008 A1
20080152704 Bonadeo et al. Jun 2008 A1
20080171083 Staniforth et al. Jul 2008 A1
20080175897 Plachetka et al. Jul 2008 A1
20080193540 Soula et al. Aug 2008 A1
20080207669 Perez et al. Aug 2008 A1
20080226702 Goldberg Sep 2008 A1
20080234237 Maddaford et al. Sep 2008 A1
20080260815 Hayes et al. Oct 2008 A1
20080260837 Namburi et al. Oct 2008 A1
20080260844 Soula et al. Oct 2008 A1
20080286343 Cengic et al. Nov 2008 A1
20080286344 Darmuzey et al. Nov 2008 A1
20080292683 Sanghvi et al. Nov 2008 A1
20080293695 Bristol et al. Nov 2008 A1
20080311162 Darmuzey et al. Dec 2008 A1
20090004267 Arkenau-Maric et al. Jan 2009 A1
20090004281 Nghiem et al. Jan 2009 A1
20090004285 Yu et al. Jan 2009 A1
20090022798 Rosenberg et al. Jan 2009 A1
20090028873 Gant et al. Jan 2009 A1
20090035315 Christgau et al. Feb 2009 A1
20090041838 Guimberteau et al. Feb 2009 A1
20090061011 Talton Mar 2009 A1
20090068247 Jay Mar 2009 A1
20090074866 Chen Mar 2009 A1
20090081290 McKenna et al. Mar 2009 A1
20090082466 Babul Mar 2009 A1
20090087483 Sison Apr 2009 A1
20090110724 Giordano Apr 2009 A1
20090124697 Cloutier et al. May 2009 A1
20090143761 Cantor et al. Jun 2009 A1
20090155193 Joabsson et al. Jun 2009 A1
20090169626 Fleischer et al. Jul 2009 A1
20090175939 Bosse et al. Jul 2009 A1
20090198248 Yeung et al. Aug 2009 A1
20090220611 Dargelas et al. Sep 2009 A1
20090220613 Odidi et al. Sep 2009 A1
20090232887 Odidi et al. Sep 2009 A1
20090238873 Chattaraj et al. Sep 2009 A1
20090246257 Modi Oct 2009 A1
20090258947 Jain et al. Oct 2009 A1
20090317355 Roth et al. Dec 2009 A1
20100003322 Lai et al. Jan 2010 A1
20100003332 Bae et al. Jan 2010 A1
20100010030 Jain et al. Jan 2010 A1
20100021543 Schierstedt Jan 2010 A1
20100041759 Wilson et al. Feb 2010 A1
20100048602 Riggs-Sauthier et al. Feb 2010 A1
20100051801 Erfurth et al. Mar 2010 A1
20100076074 Gant et al. Mar 2010 A1
20100080829 Dulieu et al. Apr 2010 A1
20100098746 King Apr 2010 A1
20100099696 Soscia et al. Apr 2010 A1
20100111830 Boyden et al. May 2010 A1
20100143449 Kolesnikov Jun 2010 A1
20100152299 Vasanthavada et al. Jun 2010 A1
20100172989 Roth et al. Jul 2010 A1
20100196471 Jain et al. Aug 2010 A1
20100196474 Han et al. Aug 2010 A1
20100204259 Tygesen et al. Aug 2010 A1
20100215737 Coulter Aug 2010 A1
20100226943 Brennan et al. Sep 2010 A1
20100226978 Petereit et al. Sep 2010 A1
20100239667 Hemmingsen et al. Sep 2010 A1
20100249045 Babul Sep 2010 A1
20100260858 Ruddy et al. Oct 2010 A1
20100266682 Davar et al. Oct 2010 A1
20100286100 First et al. Nov 2010 A1
20100291201 Shah et al. Nov 2010 A1
20100291205 Downie et al. Nov 2010 A1
20100304998 Sem Dec 2010 A1
20110003005 Venkatesh et al. Jan 2011 A1
20110003006 Venkatesh et al. Jan 2011 A1
20110008424 Chang et al. Jan 2011 A1
20110020440 Modi et al. Jan 2011 A1
20110020451 Bartholomäus et al. Jan 2011 A1
20110020776 Nielsen et al. Jan 2011 A1
20110038930 Barnscheid et al. Feb 2011 A1
20110052685 Hou et al. Mar 2011 A1
20110077238 Leech et al. Mar 2011 A1
20110091537 Castan et al. Apr 2011 A1
20110091563 Kurasawa et al. Apr 2011 A1
20110104214 Oshlack et al. May 2011 A1
20110104272 Hou May 2011 A1
20110118189 Farr et al. May 2011 A1
20110129530 Venkatesh et al. Jun 2011 A1
20110142905 Bar-Shalom et al. Jun 2011 A1
20110142943 Rariy et al. Jun 2011 A1
20110150989 Park et al. Jun 2011 A1
20110159048 Crain et al. Jun 2011 A1
20110159100 Andersen et al. Jun 2011 A1
20110160239 Brodbeck et al. Jun 2011 A1
20110165248 Machonis Jul 2011 A1
20110182987 Bawa et al. Jul 2011 A1
20110195116 Hobbs et al. Aug 2011 A1
20110195520 Leider et al. Aug 2011 A1
20110195989 Rudnic et al. Aug 2011 A1
20110207761 Losev et al. Aug 2011 A1
20110218209 Yered Sep 2011 A1
20110229562 Bar et al. Sep 2011 A1
20110230816 Copp-Howland Sep 2011 A1
20110237614 Jude-Fishburn et al. Sep 2011 A1
20110239745 Satcher, Jr. et al. Oct 2011 A1
20110245208 Diatchenko et al. Oct 2011 A1
20110262539 Bosse et al. Oct 2011 A1
20110287095 Park et al. Nov 2011 A1
20110311626 Venkatesh et al. Dec 2011 A1
20110311628 Muthusamy et al. Dec 2011 A1
20110311631 Baer et al. Dec 2011 A1
20120009129 Brzeczko Jan 2012 A1
20120010157 Polvino et al. Jan 2012 A1
20120015007 Bredenberg et al. Jan 2012 A1
20120015031 Sesha Jan 2012 A1
20120021370 Drapeau et al. Jan 2012 A1
20120022009 Bryant Jan 2012 A1
20120034306 Pollock et al. Feb 2012 A1
20120039957 Brzeczko et al. Feb 2012 A1
20120045506 Baer et al. Feb 2012 A1
20120059065 Barnscheid et al. Mar 2012 A1
20120063996 Bosch et al. Mar 2012 A1
20120064159 Chauhan et al. Mar 2012 A1
20120065220 Barnscheid et al. Mar 2012 A1
20120083506 Herry et al. Apr 2012 A1
20120088786 Dadagher et al. Apr 2012 A1
20120093929 Oksche et al. Apr 2012 A1
20120100183 Schlessinger et al. Apr 2012 A1
20120107400 Muthusamy et al. May 2012 A1
20120121594 Smith May 2012 A1
20120121724 Maibach May 2012 A1
20120135075 Mohammad May 2012 A1
20120135077 Mehta et al. May 2012 A1
20120141554 Dill Jun 2012 A1
20120164209 Shah et al. Jun 2012 A1
20120164220 Huang Jun 2012 A1
20120202838 Ghosh et al. Aug 2012 A1
20120205532 Mazza Aug 2012 A1
20120207825 Roy et al. Aug 2012 A1
20120237556 Schlessinger et al. Sep 2012 A1
20120245156 Nguyen Sep 2012 A1
20120251590 Cruz et al. Oct 2012 A1
20120282335 Venkatesh et al. Nov 2012 A1
20120289534 Pergolizzi et al. Nov 2012 A1
20120321674 Vachon et al. Dec 2012 A1
20130004415 Moudgil et al. Jan 2013 A1
20130011479 Angeli et al. Jan 2013 A1
20130017262 Mullen et al. Jan 2013 A1
20130022646 Rudnic et al. Jan 2013 A1
20130022676 Mullen et al. Jan 2013 A1
20130022677 Mullen et al. Jan 2013 A1
20130023553 Jude-Fishburn et al. Jan 2013 A1
20130028955 Tolia Jan 2013 A1
20130028970 Schwier et al. Jan 2013 A1
20130028972 Schwier et al. Jan 2013 A1
20130030360 Stopek et al. Jan 2013 A1
20130059010 Herry et al. Mar 2013 A1
20130102959 Stopek et al. Apr 2013 A1
20130115249 Vergez et al. May 2013 A1
20130122098 First et al. May 2013 A1
20130122101 Habib et al. May 2013 A1
20130123294 Lebon et al. May 2013 A1
20130129825 Billoet May 2013 A1
20130129826 Geiβler et al. May 2013 A1
20130129828 Talton May 2013 A1
20130136792 Draper et al. May 2013 A1
20130156853 Zhang et al. Jun 2013 A1
20130165467 Hayes et al. Jun 2013 A1
20130168321 Cannon et al. Jul 2013 A1
20130197021 Mohammad et al. Aug 2013 A1
20130209557 Barnscheid Aug 2013 A1
20130209561 Kao et al. Aug 2013 A1
20130217777 Kirkorian Aug 2013 A1
20130225412 Sardari Lodriche et al. Aug 2013 A1
20130225625 Barnscheid et al. Aug 2013 A1
20130225697 Barnscheid et al. Aug 2013 A1
20130230587 Pilgaonkar et al. Sep 2013 A1
20130237559 Ortiz et al. Sep 2013 A1
20130245054 Prater et al. Sep 2013 A1
20130259941 O'Donnell Oct 2013 A1
20130273153 Park et al. Oct 2013 A1
20130273162 Li Oct 2013 A1
20130280176 Diezi et al. Oct 2013 A1
20130280177 Raman et al. Oct 2013 A1
20130280338 Wening et al. Oct 2013 A1
20130303623 Barnscheid et al. Nov 2013 A1
20130330409 Mohammad Dec 2013 A1
20130345250 Fleming Dec 2013 A1
20140010873 Tygesen et al. Jan 2014 A1
20140010874 Sackler Jan 2014 A1
20140017310 Gower et al. Jan 2014 A1
20140031734 Saxena et al. Jan 2014 A1
20140045801 Rossi Feb 2014 A1
20140050787 Tygesen et al. Feb 2014 A1
20140056979 Huang Feb 2014 A1
20140066516 Clarke et al. Mar 2014 A1
20140094438 Mitchell Apr 2014 A1
20140105977 Devarakonda et al. Apr 2014 A1
20140105987 Rariy et al. Apr 2014 A1
20140112984 Arkenau-Maric et al. Apr 2014 A1
20140112989 Bartholomaus et al. Apr 2014 A1
20140127300 Tengler et al. May 2014 A1
20140171481 Liepold et al. Jun 2014 A1
20150057304 Thompson et al. Feb 2015 A1
20150283087 Vamvakas Oct 2015 A1
Foreign Referenced Citations (390)
Number Date Country
264736 Oct 1926 CA
265145 Oct 1926 CA
265559 Nov 1926 CA
2319353 Aug 1999 CA
2408106 Nov 2001 CA
2386794 Jan 2002 CA
2544404 Jun 2005 CA
2573583 Feb 2006 CA
2649265 Aug 2007 CA
2690829 Jan 2009 CA
2737307 Apr 2010 CA
2750400 Jul 2010 CA
2766179 Dec 2010 CA
2847613 Mar 2013 CA
101824144 Sep 2010 CN
101987081 Mar 2011 CN
102344534 Feb 2012 CN
102389423 Mar 2012 CN
102648985 Aug 2012 CN
103040829 Apr 2013 CN
103070840 May 2013 CN
103637987 Mar 2014 CN
103637998 Mar 2014 CN
2326141 Dec 1973 DE
2705051 Aug 1977 DE
10215067 Oct 2003 DE
10215131 Oct 2003 DE
202006014131 Jan 2007 DE
102007021549 Nov 2008 DE
103991 Mar 1984 EP
0152292 Aug 1985 EP
459387 Dec 1991 EP
1663229 Jun 2006 EP
1980245 Oct 2008 EP
2007360 Dec 2008 EP
2067471 Jun 2009 EP
2106799 Oct 2009 EP
2123626 Nov 2009 EP
2343071 Jul 2011 EP
2359812 Aug 2011 EP
2444064 Apr 2012 EP
2457900 May 2012 EP
2548863 Jan 2013 EP
2548876 Jan 2013 EP
2586607 May 2013 EP
2626358 Aug 2013 EP
2850576 Aug 2004 FR
2878158 May 2006 FR
2878161 May 2006 FR
2892937 May 2007 FR
2960775 Dec 2011 FR
135381 Dec 1919 GB
9903375 Feb 2000 HU
2009DE00453 Apr 2003 IN
2005MU01012 Aug 2004 IN
2005MU01013 Jun 2007 IN
2006KO00351 Jul 2007 IN
55084166 Jun 1980 JP
60092214 May 1985 JP
11033084 Feb 1999 JP
2009256214 Nov 2009 JP
2010053078 Mar 2010 JP
20100173976 Aug 2010 JP
2011256115 Dec 2011 JP
2013249458 Dec 2013 JP
2008026754 Mar 2008 KR
1203186 Nov 2012 KR
133984 Jul 1985 PL
WO-8503439 Aug 1985 WO
WO-9107950 Jun 1991 WO
WO-9324154 Dec 1993 WO
WO-9408551 Apr 1994 WO
WO-9418970 Sep 1994 WO
WO-9425009 Nov 1994 WO
WO-9426731 Nov 1994 WO
WO-9523591 Sep 1995 WO
WO-9614059 May 1996 WO
WO-9623486 Aug 1996 WO
WO-9704780 Feb 1997 WO
WO-9720556 Jun 1997 WO
WO-9720561 Jun 1997 WO
WO-9733566 Sep 1997 WO
WO-9803179 Jan 1998 WO
WO-9907413 Feb 1998 WO
WO-9818610 May 1998 WO
WO-9825613 Jun 1998 WO
WO-9832427 Jul 1998 WO
WO-9850044 Nov 1998 WO
WO-9850075 Nov 1998 WO
WO-9944591 Sep 1999 WO
WO-9953922 Oct 1999 WO
WO-9966919 Dec 1999 WO
WO-0021504 Apr 2000 WO
WO-0029022 May 2000 WO
WO-0029023 May 2000 WO
WO-0038649 Jul 2000 WO
WO-0061537 Oct 2000 WO
WO-0061541 Oct 2000 WO
WO-0108662 Feb 2001 WO
WO-0112584 Feb 2001 WO
WO-0115667 Mar 2001 WO
WO-0132101 May 2001 WO
WO-0132928 May 2001 WO
WO-0176576 Oct 2001 WO
WO-0185150 Nov 2001 WO
WO-0185257 Nov 2001 WO
WO-0191736 Dec 2001 WO
WO-0205647 Jan 2002 WO
WO-0232395 Apr 2002 WO
WO-0234237 May 2002 WO
WO-02051432 Jul 2002 WO
WO-02056861 Jul 2002 WO
WO-02100351 Dec 2002 WO
WO-03004009 Jan 2003 WO
WO-03013481 Feb 2003 WO
WO-03020200 Mar 2003 WO
WO-03024430 Mar 2003 WO
WO-03032990 Apr 2003 WO
WO-03034991 May 2003 WO
WO-03051878 Jun 2003 WO
WO-03063834 Aug 2003 WO
WO-03065988 Aug 2003 WO
WO-03066029 Aug 2003 WO
WO-03066030 Aug 2003 WO
WO-03068197 Aug 2003 WO
WO-03079972 Oct 2003 WO
WO-03088991 Oct 2003 WO
WO-03092648 Nov 2003 WO
WO-03101476 Dec 2003 WO
WO-2004026256 Apr 2004 WO
WO-2004039320 May 2004 WO
WO-2004045551 Jun 2004 WO
WO-2004054542 Jul 2004 WO
WO-2004064832 Aug 2004 WO
WO-2004069135 Aug 2004 WO
WO-2004062719 Sep 2004 WO
WO-2004075832 Sep 2004 WO
WO-2004082588 Sep 2004 WO
WO-2004084868 Oct 2004 WO
WO-2004108163 Dec 2004 WO
WO-2005000310 Jan 2005 WO
WO-2005000331 Jan 2005 WO
WO-2005002597 Jan 2005 WO
WO-2005004989 Jan 2005 WO
WO-2005009409 Feb 2005 WO
WO-2005028539 Mar 2005 WO
WO-2005030181 Apr 2005 WO
WO-2005030182 Apr 2005 WO
WO-2005032474 Apr 2005 WO
WO-2005032555 Apr 2005 WO
WO-2005038049 Apr 2005 WO
WO-2005046727 May 2005 WO
WO-2005051356 Jun 2005 WO
WO-2005058303 Jun 2005 WO
WO-2005063206 Jul 2005 WO
WO-2005063219 Jul 2005 WO
WO-2005079760 Sep 2005 WO
WO-2005092306 Oct 2005 WO
WO-2005102338 Nov 2005 WO
WO-2005103070 Nov 2005 WO
WO-2005107467 Nov 2005 WO
WO-2005107726 Nov 2005 WO
WO-2005123192 Dec 2005 WO
WO-2005123193 Dec 2005 WO
WO-2006014967 Feb 2006 WO
WO-2006020930 Feb 2006 WO
WO-2006024018 Mar 2006 WO
WO-2006024881 Mar 2006 WO
WO-2006030402 Mar 2006 WO
WO-2006046114 May 2006 WO
WO-2006050165 May 2006 WO
WO-2006069030 Jun 2006 WO
WO-2006069202 Jun 2006 WO
WO-2006075123 Jul 2006 WO
WO-2005070465 Aug 2006 WO
WO-2006085101 Aug 2006 WO
WO-2006092691 Sep 2006 WO
WO-2006099541 Sep 2006 WO
WO-2006103418 Oct 2006 WO
WO-2006103551 Oct 2006 WO
WO-2006105205 Oct 2006 WO
WO-2006116148 Nov 2006 WO
WO-2006133733 Dec 2006 WO
WO-2006138278 Dec 2006 WO
WO-2007021970 Feb 2007 WO
WO-2007036671 Apr 2007 WO
WO-2007050631 May 2007 WO
WO-2007056142 May 2007 WO
WO-2007058960 May 2007 WO
WO-2007070632 Jun 2007 WO
WO-2007072503 Jun 2007 WO
WO-2007087452 Aug 2007 WO
WO-2007089328 Aug 2007 WO
WO-2007094694 Aug 2007 WO
WO-2007106550 Sep 2007 WO
WO-2007128349 Nov 2007 WO
WO-2007128884 Nov 2007 WO
WO-2007131357 Nov 2007 WO
WO-2007133583 Nov 2007 WO
WO-2007135193 Nov 2007 WO
WO-2007141328 Dec 2007 WO
WO-2007149438 Dec 2007 WO
WO-2008001341 Jan 2008 WO
WO-2008007152 Jan 2008 WO
WO-2008008364 Jan 2008 WO
WO-2008011169 Jan 2008 WO
WO-2008013710 Jan 2008 WO
WO-2008021394 Feb 2008 WO
WO-2008023261 Feb 2008 WO
WO-2008027350 Mar 2008 WO
WO-2008027442 Mar 2008 WO
WO-2008033351 Mar 2008 WO
WO-2008033523 Mar 2008 WO
WO-2008057579 May 2008 WO
WO-2008057608 May 2008 WO
WO-2008060552 May 2008 WO
WO-2008063625 May 2008 WO
WO-2008067222 Jun 2008 WO
WO-2008068471 Jun 2008 WO
WO-2008070268 Jun 2008 WO
WO-2008086804 Jul 2008 WO
WO-2008097976 Aug 2008 WO
WO-2008100977 Aug 2008 WO
WO-2008106429 Sep 2008 WO
WO-2008107410 Sep 2008 WO
WO-2008108957 Sep 2008 WO
WO-2008108958 Sep 2008 WO
WO-2008108986 Sep 2008 WO
WO-2008131056 Oct 2008 WO
WO-2008131057 Oct 2008 WO
WO-2008132712 Nov 2008 WO
WO-2008133928 Nov 2008 WO
WO-2008134600 Nov 2008 WO
WO-2008135283 Nov 2008 WO
WO-2008140459 Nov 2008 WO
WO-2008140460 Nov 2008 WO
WO-2008140461 Nov 2008 WO
WO-2008141189 Nov 2008 WO
WO-2008148798 Dec 2008 WO
WO-2008155620 Dec 2008 WO
WO-2008157308 Dec 2008 WO
WO-2009002299 Dec 2008 WO
WO-2009005613 Jan 2009 WO
WO-2009005803 Jan 2009 WO
WO-2009014534 Jan 2009 WO
WO-2009021055 Feb 2009 WO
WO-2009023672 Feb 2009 WO
WO-2009026241 Feb 2009 WO
WO-2009042960 Apr 2009 WO
WO-2009047175 Apr 2009 WO
WO-2009073686 Jun 2009 WO
WO-2009076361 Jun 2009 WO
WO-2009076764 Jun 2009 WO
WO-2009089134 Jul 2009 WO
WO-2009100118 Aug 2009 WO
WO-2009104838 Aug 2009 WO
WO-2009109911 Sep 2009 WO
WO-2009114648 Sep 2009 WO
WO-2009118764 Oct 2009 WO
WO-2009120889 Oct 2009 WO
WO-2009121496 Oct 2009 WO
WO-2009124755 Oct 2009 WO
WO-2009126931 Oct 2009 WO
WO-2009137086 Nov 2009 WO
WO-2009134336 Nov 2009 WO
WO-2009143295 Nov 2009 WO
WO-2009143299 Nov 2009 WO
WO-2009152133 Dec 2009 WO
WO-2010000073 Jan 2010 WO
WO-2010017821 Feb 2010 WO
WO-2010032128 Mar 2010 WO
WO-2010033195 Mar 2010 WO
WO-2010068789 Jun 2010 WO
WO-2010069050 Jun 2010 WO
WO-2010083894 Jul 2010 WO
WO-2010089132 Aug 2010 WO
WO-2010096045 Aug 2010 WO
WO-2010103365 Sep 2010 WO
WO-2010103367 Sep 2010 WO
WO-2010123999 Oct 2010 WO
WO-2010124089 Oct 2010 WO
WO-2010127345 Nov 2010 WO
WO-2010127346 Nov 2010 WO
WO-2010132095 Nov 2010 WO
WO-2010135340 Nov 2010 WO
WO-2010140007 Dec 2010 WO
WO-2010141505 Dec 2010 WO
WO-2010150930 Dec 2010 WO
WO-2010151020 Dec 2010 WO
WO-2010151823 Dec 2010 WO
WO-2011005671 Jan 2011 WO
WO-2011006012 Jan 2011 WO
WO-2011008298 Jan 2011 WO
WO-2011009603 Jan 2011 WO
WO-2011009604 Jan 2011 WO
WO-2011011060 Jan 2011 WO
WO-2011011199 Jan 2011 WO
WO-2011011543 Jan 2011 WO
WO-2011012715 Feb 2011 WO
WO-2011039768 Apr 2011 WO
WO-2011045769 Apr 2011 WO
WO-2011057199 May 2011 WO
WO-2011066287 Jun 2011 WO
WO-2011066980 Jun 2011 WO
WO-2011068723 Jun 2011 WO
WO-2011068881 Jun 2011 WO
WO-2011084593 Jul 2011 WO
WO-2011086193 Jul 2011 WO
WO-2011088140 Jul 2011 WO
WO-2011106076 Sep 2011 WO
WO-2011107750 Sep 2011 WO
WO-2011107855 Sep 2011 WO
WO-2011120084 Oct 2011 WO
WO-2011123719 Oct 2011 WO
WO-2011123866 Oct 2011 WO
WO-2011127467 Oct 2011 WO
WO-2011139595 Nov 2011 WO
WO-2012007159 Jan 2012 WO
WO-2012011917 Jan 2012 WO
WO-2012016569 Feb 2012 WO
WO-2012020097 Feb 2012 WO
WO-2012021819 Feb 2012 WO
WO-2012028319 Mar 2012 WO
WO-2012037457 Mar 2012 WO
WO-2012052955 Apr 2012 WO
WO-2012054071 Apr 2012 WO
WO-2012054831 Apr 2012 WO
WO-2012061779 May 2012 WO
WO-2012063257 May 2012 WO
WO-2012069175 May 2012 WO
WO-2012076907 Jun 2012 WO
WO-2012077110 Jun 2012 WO
WO-2012085236 Jun 2012 WO
WO-2012085656 Jun 2012 WO
WO-2012085657 Jun 2012 WO
WO-2012087377 Jun 2012 WO
WO-2012098281 Jul 2012 WO
WO-2012106343 Aug 2012 WO
WO-2012112933 Aug 2012 WO
WO-2012112952 Aug 2012 WO
WO-2012116278 Aug 2012 WO
WO-2012116279 Aug 2012 WO
WO-2012121461 Sep 2012 WO
WO-2012127506 Sep 2012 WO
WO-2012131463 Oct 2012 WO
WO-2012139191 Oct 2012 WO
WO-2012177986 Dec 2012 WO
WO-2013000578 Jan 2013 WO
WO-2013003845 Jan 2013 WO
WO-2013010880 Jan 2013 WO
WO-2013010881 Jan 2013 WO
WO-2013015545 Jan 2013 WO
WO-2013038267 Mar 2013 WO
WO-2013038268 Mar 2013 WO
WO-2013050539 Apr 2013 WO
WO-2013057570 Apr 2013 WO
WO-2013058496 Apr 2013 WO
WO-2013059805 Apr 2013 WO
WO-2013061161 May 2013 WO
WO-2013070617 May 2013 WO
WO-2013072395 May 2013 WO
WO-2013077851 May 2013 WO
WO-2013082308 Jun 2013 WO
WO-2013083710 Jun 2013 WO
WO-2013084059 Jun 2013 WO
WO-2013093877 Jun 2013 WO
WO-2013103537 Jul 2013 WO
WO-2013119231 Aug 2013 WO
WO-2013128276 Sep 2013 WO
WO-2013128447 Sep 2013 WO
WO-2013136078 Sep 2013 WO
WO-2013138118 Sep 2013 WO
WO-2013151638 Oct 2013 WO
WO-2013155430 Oct 2013 WO
WO-2013158810 Oct 2013 WO
WO-2013158814 Oct 2013 WO
WO-2013170052 Nov 2013 WO
WO-2013171146 Nov 2013 WO
WO-2013175511 Nov 2013 WO
WO-2014001268 Jan 2014 WO
WO-2014001904 Jan 2014 WO
WO-2014001905 Jan 2014 WO
WO-2014006004 Jan 2014 WO
WO-2014011830 Jan 2014 WO
WO-2014025638 Feb 2014 WO
WO-2014045305 Mar 2014 WO
WO-2014047731 Apr 2014 WO
WO-2014059512 Apr 2014 WO
WO-2015023675 Feb 2015 WO
WO-2015023704 Feb 2015 WO
Non-Patent Literature Citations (21)
Entry
Third Party Observation dated Sep. 8, 2015 for International Application No. PCT/US2014/050737.
Gazzaniga et al., “A novel injection-molded capsular device for oral pulsatile delivery based on swellable/erodible polymers”, AAPS PharmSciTech, 2011, vol. 12, No. 1, pp. 295-303.
Soininen et al., “Effect of polyethylene glycol 20000 on bioavailability of micronized and crystalline paracetamol”, Acta Pharmaceutica Fennica, 1981, vol. 90, vol. 4, pp. 381-386.
Soininen et al., “Dissolution rate of different kinds of granulated micronized paracetamol with adjuvant incorporated either inter- or intragranularly”, Acta Pharmaceutica Fennica, 1981, vol. 90, No. 2, pp. 153-162.
Sako et al., “Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene bride and colonic drug release in dogs”, Pharmaceutical Research, 1996, vol. 13, No. 4, pp, 594-598.
Djuris et at, “Application of quality by design concepts in the development of fluidized bed granulation and tableting processes”, Journal of Pharmaceutical Sciences, 2013, vol. 102, No. 6, pp. 1869-1882.
Dahl et al., “Mechanisms to control drug release from pellets coated with a silicone elastomer aqueous dispersion”, Pharmaceutical Research, 1992, vol. 9, No. 3, pp. 398-405.
Sako, et al., “Influence of water soluble fillers in hydroxypropylmethylcellulose matrices on in vitro and in vivo drug release”, Journal of Controlled Release, 2002, vol. 81, No. 1-2, pp, 165-172.
Borini et al., “Hot melt granulation of coarse pharmaceutical powders in a spouted bed”, Powder Technology, 2009, vol. 189. No. 3, pp. 520-527.
Gohel et al., “Fabrication and Evaluation of Bi-layer Tablet Containing Conventional Paracetamol and Modified Release Diclofenac Sodium”, Indian J. Pharm Sci., 2010, vol. 72, No. 2. pp. 191-196.
Stambaugh et al., “Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients”, 2001, vol. 41, No. 5, pp. 500-506.
Sunshine et al., “Analgesic Efficacy of Controlled-Release Oxycodone in Postoperative Pain”, Journal of Clinical Pharmacology, 1996, vol. 36, No. 7, pp. 595-603.
Harris, et al., “Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users”, Journal of Clinical Pharmacology, 2014, vol. 54, No. 4, pp. 468-477.
Gosai et al., “Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US”, Int J Clin Pharmacol Ther., 2013, vol. 51, No. 11, pp. 895-907.
Upadhye et al., “Polyethylene Oxide and Ethylcellulose for Tamper Resistance and Controlled Drug Delivery”, Melt Extrusion, AAPS Advances in the Pharmaceutical Sciences Series, 2013, vol. 9, pp. 145-158.
Benziger et al., “Differential Effects of Food on the Bioavailability of Controlled-Release Oxycodone Tablets and Immediate-Release Oxycodone Solution”, Journal of Pharmaceutical Sciences. vol. 85, No. 4, pp. 407-410.
International Search Report for International Application No. PCT/US14/50737; International Filing Date Aug. 12, 2014.
Bartholomaus et al., “New Abuse Deterrent Formulation (ADP) Technology for Immediate-Release Opioids”. Drug Development & Delivery, 2013, vol. 13, No. 8, pp. 76-81.
International Search Report for International Application PCT/US2015/039336; Filing Date Jul. 7, 2015.
MP Biomedicals. Lecithin Meiting Point Properties. Retrieved Feb. 2016.
“Poloxamer”, from Wikipedia, the free encyclopedia—4 Pages.
Related Publications (1)
Number Date Country
20160015650 A1 Jan 2016 US
Provisional Applications (1)
Number Date Country
62025878 Jul 2014 US